BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, Srishord M. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011; 9: 524-530. quiz e60. [PMID: 21440669 DOI: 10.1016/j.cgh.2011.03.020] [Cited by in Crossref: 645] [Cited by in F6Publishing: 557] [Article Influence: 64.5] [Reference Citation Analysis]
Number Citing Articles
1 Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019;70:151-171. [PMID: 30266282 DOI: 10.1016/j.jhep.2018.09.014] [Cited by in Crossref: 615] [Cited by in F6Publishing: 473] [Article Influence: 205.0] [Reference Citation Analysis]
2 Bashiri H, Bozorgomid A, Shojaeimotlagh V. Efficacy of Hijamat (wet cupping therapy) in Iranian patients with nonalcoholic fatty liver disease: a controlled clinical trial. Turk J Med Sci 2020;50:354-9. [PMID: 31999405 DOI: 10.3906/sag-1907-82] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Papagianni M, Sofogianni A, Tziomalos K. Non-invasive methods for the diagnosis of nonalcoholic fatty liver disease. World J Hepatol 2015;7:638-48. [PMID: 25866601 DOI: 10.4254/wjh.v7.i4.638] [Cited by in Crossref: 43] [Cited by in F6Publishing: 33] [Article Influence: 7.2] [Reference Citation Analysis]
4 Czaja MJ, Ding WX, Donohue TM Jr, Friedman SL, Kim JS, Komatsu M, Lemasters JJ, Lemoine A, Lin JD, Ou JH, Perlmutter DH, Randall G, Ray RB, Tsung A, Yin XM. Functions of autophagy in normal and diseased liver. Autophagy. 2013;9:1131-1158. [PMID: 23774882 DOI: 10.4161/auto.25063] [Cited by in Crossref: 278] [Cited by in F6Publishing: 258] [Article Influence: 34.8] [Reference Citation Analysis]
5 Sarli PM, Manousopoulou A, Efthymiou E, Zouridis A, Potiris A, Pervanidou P, Panoulis K, Vlahos N, Deligeoroglou E, Garbis SD, Eleftheriades M. Liver Proteome Profile of Growth Restricted and Appropriately Grown Newborn Wistar Rats Associated With Maternal Undernutrition. Front Endocrinol (Lausanne) 2021;12:684220. [PMID: 34127923 DOI: 10.3389/fendo.2021.684220] [Reference Citation Analysis]
6 Morrison M, Hughes HY, Naggie S, Syn WK. Nonalcoholic Fatty Liver Disease Among Individuals with HIV Mono-infection: A Growing Concern? Dig Dis Sci 2019;64:3394-401. [PMID: 31643035 DOI: 10.1007/s10620-019-05861-7] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Acharya C, Bajaj JS. Gut Microbiota and Complications of Liver Disease. Gastroenterol Clin North Am. 2017;46:155-169. [PMID: 28164848 DOI: 10.1016/j.gtc.2016.09.013] [Cited by in Crossref: 39] [Cited by in F6Publishing: 28] [Article Influence: 13.0] [Reference Citation Analysis]
8 Fleischman MW, Budoff M, Zeb I, Li D, Foster T. NAFLD prevalence differs among hispanic subgroups: the Multi-Ethnic Study of Atherosclerosis. World J Gastroenterol 2014;20:4987-93. [PMID: 24803810 DOI: 10.3748/wjg.v20.i17.4987] [Cited by in CrossRef: 52] [Cited by in F6Publishing: 44] [Article Influence: 8.7] [Reference Citation Analysis]
9 Reddy SK, Marsh JW, Varley PR, Mock BK, Chopra KB, Geller DA, Tsung A. Underlying steatohepatitis, but not simple hepatic steatosis, increases morbidity after liver resection: a case-control study. Hepatology. 2012;56:2221-2230. [PMID: 22767263 DOI: 10.1002/hep.25935] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 6.4] [Reference Citation Analysis]
10 Jensen VS, Tveden-Nyborg P, Zacho-Rasmussen C, Quaade ML, Ipsen DH, Hvid H, Fledelius C, Wulff EM, Lykkesfeldt J. Variation in diagnostic NAFLD/NASH read-outs in paired liver samples from rodent models. J Pharmacol Toxicol Methods 2020;101:106651. [PMID: 31733366 DOI: 10.1016/j.vascn.2019.106651] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
11 Burnham B, Wallington S, Jillson IA, Trandafili H, Shetty K, Wang J, Loffredo CA. Knowledge, attitudes, and beliefs of patients with chronic liver disease. Am J Health Behav. 2014;38:737-744. [PMID: 24933143 DOI: 10.5993/ajhb.38.5.11] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 3.2] [Reference Citation Analysis]
12 Wijarnpreecha K, Thongprayoon C, Ungprasert P. Coffee consumption and risk of nonalcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2017;29:e8-e12. [PMID: 27824642 DOI: 10.1097/MEG.0000000000000776] [Cited by in Crossref: 53] [Cited by in F6Publishing: 23] [Article Influence: 13.3] [Reference Citation Analysis]
13 Tziomalos K. Lipid-lowering agents in the management of nonalcoholic fatty liver disease. World J Hepatol 2014;6:738-44. [PMID: 25349644 DOI: 10.4254/wjh.v6.i10.738] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
14 Pham T, Dick TB, Charlton MR. Nonalcoholic Fatty Liver Disease and Liver Transplantation. Clin Liver Dis 2016;20:403-17. [PMID: 27063277 DOI: 10.1016/j.cld.2015.10.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
15 Henao-Mejia J, Elinav E, Thaiss CA, Licona-Limon P, Flavell RA. Role of the intestinal microbiome in liver disease. J Autoimmun. 2013;46:66-73. [PMID: 24075647 DOI: 10.1016/j.jaut.2013.07.001] [Cited by in Crossref: 106] [Cited by in F6Publishing: 93] [Article Influence: 13.3] [Reference Citation Analysis]
16 Leon M, Varon J, Surani S. When a liver transplant recipient goes back to alcohol abuse: Should we be more selective? World J Gastroenterol 2016;22:4789-93. [PMID: 27239105 DOI: 10.3748/wjg.v22.i20.4789] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
17 Tapper EB, Martinez-macias R, Duarte-rojo A. Is Exercise Beneficial and Safe in Patients with Cirrhosis and Portal Hypertension? Curr Hepatology Rep 2018;17:175-83. [DOI: 10.1007/s11901-018-0404-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
18 Zhu L, Baker SS, Gill C, Liu W, Alkhouri R, Baker RD, Gill SR. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology. 2013;57:601-609. [PMID: 23055155 DOI: 10.1002/hep.26093] [Cited by in Crossref: 769] [Cited by in F6Publishing: 681] [Article Influence: 96.1] [Reference Citation Analysis]
19 Kwak MS, Kim D. Non-alcoholic fatty liver disease and lifestyle modifications, focusing on physical activity. Korean J Intern Med 2018;33:64-74. [PMID: 29202557 DOI: 10.3904/kjim.2017.343] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 8.0] [Reference Citation Analysis]
20 Lauschke VM, Mkrtchian S, Ingelman-Sundberg M. The role of microRNAs in liver injury at the crossroad between hepatic cell death and regeneration. Biochem Biophys Res Commun 2017;482:399-407. [PMID: 27789285 DOI: 10.1016/j.bbrc.2016.10.084] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
21 Lallukka S, Sevastianova K, Perttilä J, Hakkarainen A, Orho-Melander M, Lundbom N, Olkkonen VM, Yki-Järvinen H. Adipose tissue is inflamed in NAFLD due to obesity but not in NAFLD due to genetic variation in PNPLA3. Diabetologia. 2013;56:886-892. [PMID: 23334462 DOI: 10.1007/s00125-013-2829-9] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 4.5] [Reference Citation Analysis]
22 Vallet-Pichard A, Parlati L, Pol S. [Epidemiology of non-alcoholic steatohepatitis. Extent/burden of the problem and its impact on public health]. Presse Med 2019;48:1459-67. [PMID: 31757728 DOI: 10.1016/j.lpm.2019.08.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Major JM, Sargent JD, Graubard BI, Carlos HA, Hollenbeck AR, Altekruse SF, Freedman ND, McGlynn KA. Local geographic variation in chronic liver disease and hepatocellular carcinoma: contributions of socioeconomic deprivation, alcohol retail outlets, and lifestyle. Ann Epidemiol. 2014;24:104-110. [PMID: 24332863 DOI: 10.1016/j.annepidem.2013.11.006] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
24 Stepanova M, Lam B, Younossi Y, Srishord MK, Younossi ZM. Association of hepatitis C with insulin resistance and type 2 diabetes in US general population: the impact of the epidemic of obesity. J Viral Hepat 2012;19:341-5. [PMID: 22497813 DOI: 10.1111/j.1365-2893.2011.01554.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 3.7] [Reference Citation Analysis]
25 Kumar V, Xin X, Ma J, Tan C, Osna N, Mahato RI. Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis. Adv Drug Deliv Rev 2021;:113888. [PMID: 34314787 DOI: 10.1016/j.addr.2021.113888] [Reference Citation Analysis]
26 Ilbeigi D, Nourbakhsh M, Pasalar P, Meshkani R, Shokri Afra H, Panahi GH, Borji M, Sharifi R. Nicotinamide Phosphoribosyltransferase Knockdown Leads to Lipid Accumulation in HepG2 Cells through The SIRT1-AMPK Pathway. Cell J 2020;22:125-32. [PMID: 32779442 DOI: 10.22074/cellj.2020.7013] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Peleg N, Issachar A, Sneh-Arbib O, Shlomai A. AST to Platelet Ratio Index and fibrosis 4 calculator scores for non-invasive assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease. Dig Liver Dis. 2017;49:1133-1138. [PMID: 28572039 DOI: 10.1016/j.dld.2017.05.002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
28 Batra S, Machicao VI, Bynon JS, Mehta S, Tanikella R, Krowka MJ, Zacks S, Trotter J, Roberts KE, Brown RS. The impact of left ventricular hypertrophy on survival in candidates for liver transplantation. Liver Transpl. 2014;20:705-712. [PMID: 24659368 DOI: 10.1002/lt.23875] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
29 Russo MW, Koteish AA, Fuchs M, Reddy KG, Fix OK. Workforce in hepatology: Update and a critical need for more information. Hepatology 2017;65:336-40. [PMID: 27628621 DOI: 10.1002/hep.28810] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
30 Chen PC, Kao WY, Cheng YL, Wang YJ, Hou MC, Wu JC, Su CW. The correlation between fatty liver disease and chronic kidney disease. J Formos Med Assoc. 2020;119:42-50. [PMID: 30876789 DOI: 10.1016/j.jfma.2019.02.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
31 Mahfood Haddad T, Hamdeh S, Kanmanthareddy A, Alla VM. Nonalcoholic fatty liver disease and the risk of clinical cardiovascular events: A systematic review and meta-analysis. Diabetes Metab Syndr. 2017;11 Suppl 1:S209-S216. [PMID: 28017631 DOI: 10.1016/j.dsx.2016.12.033] [Cited by in Crossref: 65] [Cited by in F6Publishing: 56] [Article Influence: 13.0] [Reference Citation Analysis]
32 Leitão HS, Paulino C, Rodrigues D, Gonçalves SI, Marques C, Carvalheiro M, Geraldes CF, Caseiro-alves F. MR Fat Fraction Mapping. Academic Radiology 2013;20:957-61. [DOI: 10.1016/j.acra.2013.05.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
33 Banerjee R, Pavlides M, Tunnicliffe EM, Piechnik SK, Sarania N, Philips R, Collier JD, Booth JC, Schneider JE, Wang LM, Delaney DW, Fleming KA, Robson MD, Barnes E, Neubauer S. Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease. J Hepatol. 2014;60:69-77. [PMID: 24036007 DOI: 10.1016/j.jhep.2013.09.002] [Cited by in Crossref: 239] [Cited by in F6Publishing: 198] [Article Influence: 29.9] [Reference Citation Analysis]
34 Han E, Lee YH. Non-Alcoholic Fatty Liver Disease: The Emerging Burden in Cardiometabolic and Renal Diseases. Diabetes Metab J 2017;41:430-7. [PMID: 29199410 DOI: 10.4093/dmj.2017.41.6.430] [Cited by in Crossref: 34] [Cited by in F6Publishing: 23] [Article Influence: 8.5] [Reference Citation Analysis]
35 Wallert M, Börmel L, Lorkowski S. Inflammatory Diseases and Vitamin E-What Do We Know and Where Do We Go? Mol Nutr Food Res 2021;65:e2000097. [PMID: 32692879 DOI: 10.1002/mnfr.202000097] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
36 Shouhed D, Steggerda J, Burch M, Noureddin M. The role of bariatric surgery in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Expert Rev Gastroenterol Hepatol. 2017;11:797-811. [PMID: 28712339 DOI: 10.1080/17474124.2017.1355731] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
37 Wang D, Lin H, Xia M, Aleteng Q, Li X, Ma H, Pan B, Gao J, Gao X. Vitamin D Levels Are Inversely Associated with Liver Fat Content and Risk of Non-Alcoholic Fatty Liver Disease in a Chinese Middle-Aged and Elderly Population: The Shanghai Changfeng Study. PLoS One. 2016;11:e0157515. [PMID: 27284686 DOI: 10.1371/journal.pone.0157515] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
38 Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 2012;55:885-904. [DOI: 10.1007/s00125-011-2446-4] [Cited by in Crossref: 366] [Cited by in F6Publishing: 322] [Article Influence: 40.7] [Reference Citation Analysis]
39 Kaliora AC, Gioxari A, Kalafati IP, Diolintzi A, Kokkinos A, Dedoussis GV. The Effectiveness of Mediterranean Diet in Nonalcoholic Fatty Liver Disease Clinical Course: An Intervention Study. J Med Food. 2019;22:729-740. [PMID: 31290733 DOI: 10.1089/jmf.2018.0020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
40 Hassan K, Bhalla V, El Regal ME, A-Kader HH. Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemic. World J Gastroenterol. 2014;20:12082-12101. [PMID: 25232245 DOI: 10.3748/wjg.v20.i34.12082] [Cited by in CrossRef: 104] [Cited by in F6Publishing: 81] [Article Influence: 17.3] [Reference Citation Analysis]
41 Boursier J, Diehl AM. Nonalcoholic Fatty Liver Disease and the Gut Microbiome. Clin Liver Dis 2016;20:263-75. [PMID: 27063268 DOI: 10.1016/j.cld.2015.10.012] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 8.3] [Reference Citation Analysis]
42 Mishra A, Younossi ZM. Epidemiology and Natural History of Non-alcoholic Fatty Liver Disease. J Clin Exp Hepatol. 2012;2:135-144. [PMID: 25755422 DOI: 10.1016/s0973-6883(12)60102-9] [Cited by in Crossref: 51] [Cited by in F6Publishing: 26] [Article Influence: 5.7] [Reference Citation Analysis]
43 Noureddin M, Zhang A, Loomba R. Promising therapies for treatment of nonalcoholic steatohepatitis. Expert Opin Emerg Drugs 2016;21:343-57. [PMID: 27501374 DOI: 10.1080/14728214.2016.1220533] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
44 Locke JE, Shelton B, Orandi B, Olthoff K, Pomfret E, Forde KA, Sawinski D, Gray M, Ascher N. Obesity is a risk factor for progression to kidney transplant waitlisting after liver transplantation. Clin Transplant 2021;35:e14317. [PMID: 33866616 DOI: 10.1111/ctr.14317] [Reference Citation Analysis]
45 Venkatesan C, Younossi ZM, Groszmann RJ, Iwakiri Y, Taddei TH. Potential mechanisms underlying the associations between liver enzymes and risk for type 2 diabetes. Hepatology 2012;55:968-70. [DOI: 10.1002/hep.24769] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
46 Hagström H, Nasr P, Ekstedt M, Hammar U, Stål P, Hultcrantz R, Kechagias S. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. Journal of Hepatology 2017;67:1265-73. [DOI: 10.1016/j.jhep.2017.07.027] [Cited by in Crossref: 332] [Cited by in F6Publishing: 288] [Article Influence: 83.0] [Reference Citation Analysis]
47 Morrell A, Tallino S, Yu L, Burkhead JL. The role of insufficient copper in lipid synthesis and fatty-liver disease. IUBMB Life 2017;69:263-70. [PMID: 28271632 DOI: 10.1002/iub.1613] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 10.3] [Reference Citation Analysis]
48 Zhu F, Li YM, Feng TT, Wu Y, Zhang HX, Jin GY, Liu JP. Freeze-dried Si-Ni-San powder can ameliorate high fat diet-induced non-alcoholic fatty liver disease. World J Gastroenterol. 2019;25:3056-3068. [PMID: 31293341 DOI: 10.3748/wjg.v25.i24.3056] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
49 Zhu JZ, Dai YN, Wang YM, Zhou QY, Yu CH, Li YM. Prevalence of Nonalcoholic Fatty Liver Disease and Economy. Dig Dis Sci 2015;60:3194-202. [PMID: 26017679 DOI: 10.1007/s10620-015-3728-3] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 9.2] [Reference Citation Analysis]
50 Long MT, Wang N, Larson MG, Mitchell GF, Palmisano J, Vasan RS, Hoffmann U, Speliotes EK, Vita JA, Benjamin EJ, Fox CS, Hamburg NM. Nonalcoholic fatty liver disease and vascular function: cross-sectional analysis in the Framingham heart study. Arterioscler Thromb Vasc Biol 2015;35:1284-91. [PMID: 25745056 DOI: 10.1161/ATVBAHA.114.305200] [Cited by in Crossref: 39] [Cited by in F6Publishing: 21] [Article Influence: 6.5] [Reference Citation Analysis]
51 Birerdinc A, Stepanova M, Pawloski L, Younossi ZM. Caffeine is protective in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2012;35:76-82. [PMID: 22059453 DOI: 10.1111/j.1365-2036.2011.04916.x] [Cited by in Crossref: 95] [Cited by in F6Publishing: 76] [Article Influence: 9.5] [Reference Citation Analysis]
52 Setiawan VW, Hernandez BY, Lu SC, Stram DO, Wilkens LR, Le Marchand L, Henderson BE. Diabetes and racial/ethnic differences in hepatocellular carcinoma risk: the multiethnic cohort. J Natl Cancer Inst. 2014;106:pii: dju326. [PMID: 25326644 DOI: 10.1093/jnci/dju326] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
53 Xia M, Bian H, Zhu X, Yan H, Chang X, Zhang L, Lin H, Hu X, Gao X. Serum folic acid levels are associated with the presence and severity of liver steatosis in Chinese adults. Clinical Nutrition 2018;37:1752-8. [DOI: 10.1016/j.clnu.2017.06.021] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
54 Lee S, Ko BJ, Gong Y, Han K, Lee A, Han BD, Yoon YJ, Park S, Kim JH, Mantzoros CS. Self-reported eating speed in relation to non-alcoholic fatty liver disease in adults. Eur J Nutr 2016;55:327-33. [PMID: 25648740 DOI: 10.1007/s00394-015-0851-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
55 Wu W, Wu C, Wang Y, Hung H, Yang H, Kao W, Su C, Wu J, Chan W, Lin H, Lee F, Lee S. Updated thresholds for serum alanine aminotransferase level in a large-scale population study composed of 34 346 subjects. Aliment Pharmacol Ther 2012;36:560-8. [DOI: 10.1111/j.1365-2036.2012.05224.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 4.3] [Reference Citation Analysis]
56 Neuman MG, French SW, French BA, Seitz HK, Cohen LB, Mueller S, Osna NA, Kharbanda KK, Seth D, Bautista A. Alcoholic and non-alcoholic steatohepatitis. Exp Mol Pathol. 2014;97:492-510. [PMID: 25217800 DOI: 10.1016/j.yexmp.2014.09.005] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 5.9] [Reference Citation Analysis]
57 Khalili M, Lombardero M, Chung RT, Terrault NA, Ghany MG, Kim WR, Lau D, Lisker-Melman M, Sanyal A, Lok AS; HBRN. Diabetes and prediabetes in patients with hepatitis B residing in North America. Hepatology. 2015;62:1364-1374. [PMID: 26390278 DOI: 10.1002/hep.28110] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
58 Nagahashi M, Takabe K, Liu R, Peng K, Wang X, Wang Y, Hait NC, Wang X, Allegood JC, Yamada A, Aoyagi T, Liang J, Pandak WM, Spiegel S, Hylemon PB, Zhou H. Conjugated bile acid-activated S1P receptor 2 is a key regulator of sphingosine kinase 2 and hepatic gene expression. Hepatology. 2015;61:1216-1226. [PMID: 25363242 DOI: 10.1002/hep.27592] [Cited by in Crossref: 93] [Cited by in F6Publishing: 81] [Article Influence: 15.5] [Reference Citation Analysis]
59 Booi AN, Menendez J, Norton HJ, Anderson WE, Ellis AC. Validation of a Screening Tool to Identify Undernutrition in Ambulatory Patients With Liver Cirrhosis. Nutr Clin Pract. 2015;30:683-689. [PMID: 26024676 DOI: 10.1177/0884533615587537] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
60 Wang C, Zhang Y, Xing D, Zhang R. PROTACs technology for targeting non-oncoproteins: Advances and perspectives. Bioorg Chem 2021;114:105109. [PMID: 34175722 DOI: 10.1016/j.bioorg.2021.105109] [Reference Citation Analysis]
61 Roth CG, Marzio DH, Guglielmo FF. Contributions of Magnetic Resonance Imaging to Gastroenterological Practice: MRIs for GIs. Dig Dis Sci 2018;63:1102-22. [PMID: 29549474 DOI: 10.1007/s10620-018-4991-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
62 Szafraniec E, Tott S, Kus E, Augustynska D, Jasztal A, Filipek A, Chlopicki S, Baranska M. Vibrational spectroscopy-based quantification of liver steatosis. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2019;1865:165526. [DOI: 10.1016/j.bbadis.2019.08.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Crabb DW, Im GY, Szabo G, Mellinger JL, Lucey MR. Diagnosis and Treatment of Alcohol‐Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases. Hepatology 2020;71:306-33. [DOI: 10.1002/hep.30866] [Cited by in Crossref: 117] [Cited by in F6Publishing: 87] [Article Influence: 117.0] [Reference Citation Analysis]
64 Jirapinyo P, Thompson CC. Treatment of NASH with Gastric Bypass. Curr Gastroenterol Rep 2018;20. [DOI: 10.1007/s11894-018-0653-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
65 Sharifnia T, Antoun J, Verriere TG, Suarez G, Wattacheril J, Wilson KT, Peek RM, Abumrad NN, Flynn CR. Hepatic TLR4 signaling in obese NAFLD. Am J Physiol Gastrointest Liver Physiol. 2015;309:G270-G278. [PMID: 26113297 DOI: 10.1152/ajpgi.00304.2014] [Cited by in Crossref: 110] [Cited by in F6Publishing: 98] [Article Influence: 18.3] [Reference Citation Analysis]
66 Bergholm R, Sevastianova K, Santos A, Kotronen A, Urjansson M, Hakkarainen A, Lundbom J, Tiikkainen M, Rissanen A, Lundbom N, Yki-järvinen H. CB1 blockade-induced weight loss over 48 weeks decreases liver fat in proportion to weight loss in humans. Int J Obes 2013;37:699-703. [DOI: 10.1038/ijo.2012.116] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
67 Christensen CU, Glavind E, Thomsen KL, Kim YO, Heebøll S, Schuppan D, Hamilton-Dutoit S, Würtz Heegaard C, Grønbæk H. Niemann-Pick type C2 protein supplementation in experimental non-alcoholic fatty liver disease. PLoS One 2018;13:e0192728. [PMID: 29522534 DOI: 10.1371/journal.pone.0192728] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
68 Asfari MM, Sarmini MT, Baidoun F, Al-Khadra Y, Ezzaizi Y, Dasarathy S, McCullough A. Association of non-alcoholic fatty liver disease and polycystic ovarian syndrome. BMJ Open Gastroenterol. 2020;7. [PMID: 32784205 DOI: 10.1136/bmjgast-2019-000352] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
69 Hyysalo J, Männistö VT, Zhou Y, Arola J, Kärjä V, Leivonen M, Juuti A, Jaser N, Lallukka S, Käkelä P. A population-based study on the prevalence of NASH using scores validated against liver histology. J Hepatol. 2014;60:839-846. [PMID: 24333862 DOI: 10.1016/j.jhep.2013.12.009] [Cited by in Crossref: 76] [Cited by in F6Publishing: 67] [Article Influence: 9.5] [Reference Citation Analysis]
70 Wong RJ, Gish RG, Cheung R, Chitnis AS. Low Prevalence of Vaccination or Documented Immunity to Hepatitis A and Hepatitis B Viruses Among Individuals with Chronic Liver Disease. Am J Med 2021;134:882-92. [PMID: 33775642 DOI: 10.1016/j.amjmed.2021.02.008] [Reference Citation Analysis]
71 Liu A, Galoosian A, Kaswala D, Li AA, Gadiparthi C, Cholankeril G, Kim D, Ahmed A. Nonalcoholic Fatty Liver Disease: Epidemiology, Liver Transplantation Trends and Outcomes, and Risk of Recurrent Disease in the Graft. J Clin Transl Hepatol. 2018;6:420-424. [PMID: 30637220 DOI: 10.14218/jcth.2018.00010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
72 Josan S, Billingsley K, Orduna J, Park JM, Luong R, Yu L, Hurd R, Pfefferbaum A, Spielman D, Mayer D. Assessing inflammatory liver injury in an acute CCl4 model using dynamic 3D metabolic imaging of hyperpolarized [1-(13)C]pyruvate. NMR Biomed. 2015;28:1671-1677. [PMID: 26474216 DOI: 10.1002/nbm.3431] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
73 Singh A, Le P, Lopez R, Alkhouri N. The utility of noninvasive scores in assessing the prevalence of nonalcoholic fatty liver disease and advanced fibrosis in type 1 diabetic patients. Hepatol Int 2018;12:37-43. [PMID: 29318450 DOI: 10.1007/s12072-017-9840-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
74 Huang F, Liu H, Lei Z, Li Z, Zhang T, Yang M, Zhou K, Sun C. Long noncoding RNA CCAT1 inhibits miR-613 to promote nonalcoholic fatty liver disease via increasing LXRα transcription. J Cell Physiol 2020;235:9819-33. [PMID: 32413192 DOI: 10.1002/jcp.29795] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
75 Karrar A, Stepanova M, Alaparthi L, Lingam S, Younoszai Z, Zheng L, Malik KS, Younossi E, Monge F, Hunt SL. Anti-adipocyte antibody response in patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2015;30:900-908. [PMID: 25469790 DOI: 10.1111/jgh.12856] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
76 Alam S, Gupta UD, Alam M, Kabir J, Chowdhury ZR, Alam AKMK. Clinical, anthropometric, biochemical, and histological characteristics of nonobese nonalcoholic fatty liver disease patients of Bangladesh. Indian J Gastroenterol 2014;33:452-7. [DOI: 10.1007/s12664-014-0488-5] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 5.4] [Reference Citation Analysis]
77 Marchisello S, Di Pino A, Scicali R, Urbano F, Piro S, Purrello F, Rabuazzo AM. Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview. Int J Mol Sci 2019;20:E1948. [PMID: 31010049 DOI: 10.3390/ijms20081948] [Cited by in Crossref: 51] [Cited by in F6Publishing: 40] [Article Influence: 25.5] [Reference Citation Analysis]
78 Ghaoui R, Garb J, Gordon F, Pomfret E. Impact of geography on organ allocation: Beyond the distance to the transplantation center. World J Hepatol 2015;7:1782-7. [PMID: 26167251 DOI: 10.4254/wjh.v7.i13.1782] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
79 Bajaj JS, Hylemon PB, Younossi Z. The Intestinal Microbiota and Liver Disease. Am J Gastroenterol Suppl 2012;1:9-14. [DOI: 10.1038/ajgsup.2012.3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 10] [Article Influence: 3.4] [Reference Citation Analysis]
80 D'Avola D, Labgaa I, Villanueva A. Natural history of nonalcoholic steatohepatitis/nonalcoholic fatty liver disease-hepatocellular carcinoma: Magnitude of the problem from a hepatology clinic perspective. Clin Liver Dis (Hoboken) 2016;8:100-4. [PMID: 31041073 DOI: 10.1002/cld.579] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
81 Neeland IJ, Yokoo T, Leinhard OD, Lavie CJ. 21st Century Advances in Multimodality Imaging of Obesity for Care of the Cardiovascular Patient. JACC Cardiovasc Imaging 2021;14:482-94. [PMID: 32305476 DOI: 10.1016/j.jcmg.2020.02.031] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
82 Henao-Mejia J, Elinav E, Thaiss CA, Flavell RA. The intestinal microbiota in chronic liver disease. Adv Immunol. 2013;117:73-97. [PMID: 23611286 DOI: 10.1016/b978-0-12-410524-9.00003-7] [Cited by in Crossref: 36] [Cited by in F6Publishing: 23] [Article Influence: 4.5] [Reference Citation Analysis]
83 Kim D, Touros A, Kim WR. Nonalcoholic Fatty Liver Disease and Metabolic Syndrome. Clin Liver Dis 2018;22:133-40. [PMID: 29128053 DOI: 10.1016/j.cld.2017.08.010] [Cited by in Crossref: 71] [Cited by in F6Publishing: 58] [Article Influence: 17.8] [Reference Citation Analysis]
84 Marušić M, Paić M, Knobloch M, Liberati Pršo AM. NAFLD, Insulin Resistance, and Diabetes Mellitus Type 2. Can J Gastroenterol Hepatol 2021;2021:6613827. [PMID: 33681089 DOI: 10.1155/2021/6613827] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
85 Venkatesh SK, Ehman RL. Magnetic resonance elastography of liver. Magn Reson Imaging Clin N Am. 2014;22:433-446. [PMID: 25086938 DOI: 10.1016/j.mric.2014.05.001] [Cited by in Crossref: 100] [Cited by in F6Publishing: 79] [Article Influence: 16.7] [Reference Citation Analysis]
86 Koola JD, Ho SB, Cao A, Chen G, Perkins AM, Davis SE, Matheny ME. Predicting 30-Day Hospital Readmission Risk in a National Cohort of Patients with Cirrhosis. Dig Dis Sci 2020;65:1003-31. [PMID: 31531817 DOI: 10.1007/s10620-019-05826-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
87 Kim BY, Jung CH, Mok JO, Kang SK, Kim CH. Prevalences of diabetic retinopathy and nephropathy are lower in Korean type 2 diabetic patients with non-alcoholic fatty liver disease. J Diabetes Investig 2014;5:170-5. [PMID: 24843757 DOI: 10.1111/jdi.12139] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
88 Corrado RL, Torres DM, Harrison SA. Review of Treatment Options for Nonalcoholic Fatty Liver Disease. Medical Clinics of North America 2014;98:55-72. [DOI: 10.1016/j.mcna.2013.09.001] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
89 Zhang X, Ji R, Sun H, Peng J, Ma X, Wang C, Fu Y, Bao L, Jin Y. Scutellarin ameliorates nonalcoholic fatty liver disease through the PPARγ/PGC-1α-Nrf2 pathway. Free Radic Res 2018;52:198-211. [PMID: 29400110 DOI: 10.1080/10715762.2017.1422602] [Cited by in F6Publishing: 14] [Reference Citation Analysis]
90 Balakrishnan M, El-Serag HB, Kanwal F, Thrift AP. Shiftwork Is Not Associated with Increased Risk of NAFLD: Findings from the National Health and Nutrition Examination Survey. Dig Dis Sci 2017;62:526-33. [PMID: 27995401 DOI: 10.1007/s10620-016-4401-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
91 Cleveland ER, Ning H, Vos MB, Lewis CE, Rinella ME, Carr JJ, Lloyd-Jones DM, VanWagner LB. Low Awareness of Nonalcoholic Fatty Liver Disease in a Population-Based Cohort Sample: the CARDIA Study. J Gen Intern Med 2019;34:2772-8. [PMID: 31595464 DOI: 10.1007/s11606-019-05340-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
92 Mejia LM. Oral Manifestations of Gastrointestinal Disorders. Atlas Oral Maxillofac Surg Clin North Am 2017;25:93-104. [PMID: 28778312 DOI: 10.1016/j.cxom.2017.04.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
93 Sharma S, Stine JG, Verbeek T, Bezinover D. Management of Patients With Non-alcoholic Steatohepatitis Undergoing Liver Transplantation: Considerations for the Anesthesiologist. J Cardiothorac Vasc Anesth 2021:S1053-0770(21)00601-7. [PMID: 34391652 DOI: 10.1053/j.jvca.2021.07.020] [Reference Citation Analysis]
94 Price JC, Dodge JL, Ma Y, Scherzer R, Korn N, Tillinghast K, Peters MG, Noworolski S, Tien PC. Controlled attenuation parameter and magnetic resonance spectroscopy-measured liver steatosis are discordant in obese HIV-infected adults. AIDS 2017;31:2119-25. [PMID: 28723710 DOI: 10.1097/QAD.0000000000001601] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
95 Sun C, Fan JG, Qiao L. Potential epigenetic mechanism in non-alcoholic Fatty liver disease. Int J Mol Sci. 2015;16:5161-5179. [PMID: 25751727 DOI: 10.3390/ijms16035161] [Cited by in Crossref: 53] [Cited by in F6Publishing: 43] [Article Influence: 8.8] [Reference Citation Analysis]
96 Chandan S, Mohan BP, Khan SR, Facciorusso A, Ramai D, Kassab LL, Bhogal N, Asokkumar R, Lopez-Nava G, McDonough S, Adler DG. Efficacy and Safety of Intragastric Balloon (IGB) in Non-alcoholic Fatty Liver Disease (NAFLD): a Comprehensive Review and Meta-analysis. Obes Surg 2021;31:1271-9. [PMID: 33409973 DOI: 10.1007/s11695-020-05084-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
97 Goh GB, McCullough AJ. Natural History of Nonalcoholic Fatty Liver Disease. Dig Dis Sci 2016;61:1226-33. [PMID: 27003142 DOI: 10.1007/s10620-016-4095-4] [Cited by in Crossref: 67] [Cited by in F6Publishing: 56] [Article Influence: 13.4] [Reference Citation Analysis]
98 Samir AE, Dhyani M, Vij A, Bhan AK, Halpern EF, Méndez-Navarro J, Corey KE, Chung RT. Shear-wave elastography for the estimation of liver fibrosis in chronic liver disease: determining accuracy and ideal site for measurement. Radiology 2015;274:888-96. [PMID: 25393946 DOI: 10.1148/radiol.14140839] [Cited by in Crossref: 105] [Cited by in F6Publishing: 90] [Article Influence: 15.0] [Reference Citation Analysis]
99 Serrano OK, Peterson KJ, Vock DM, Berglund D, Kandaswamy R, Lake JR, Pruett TL, Chinnakotla S. Clinical Impact of Antecedent Bariatric Surgery on Liver Transplant Outcomes: A Retrospective Matched Case-control Study. Transplantation 2021;105:1280-4. [PMID: 32590608 DOI: 10.1097/TP.0000000000003378] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
100 Chung J, Koo K, Lian F, Hu KQ, Ernst H, Wang XD. Apo-10'-lycopenoic acid, a lycopene metabolite, increases sirtuin 1 mRNA and protein levels and decreases hepatic fat accumulation in ob/ob mice. J Nutr 2012;142:405-10. [PMID: 22259190 DOI: 10.3945/jn.111.150052] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 5.0] [Reference Citation Analysis]
101 Gracious BL, Bhatt R, Potter C. Nonalcoholic Fatty Liver Disease and Fibrosis in Youth Taking Psychotropic Medications: Literature Review, Case Reports, and Management. Journal of Child and Adolescent Psychopharmacology 2015;25:602-10. [DOI: 10.1089/cap.2015.0007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
102 Dinani A, Sanyal A. Nonalcoholic fatty liver disease: implications for cardiovascular risk. Cardiovasc Endocrinol 2017;6:62-72. [PMID: 31646122 DOI: 10.1097/XCE.0000000000000126] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
103 Portincasa P, Krawczyk M, Machill A, Lammert F, Di Ciaula A. Hepatic consequences of COVID-19 infection. Lapping or biting? Eur J Intern Med. 2020;77:18-24. [PMID: 32507608 DOI: 10.1016/j.ejim.2020.05.035] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 35.0] [Reference Citation Analysis]
104 Al-Shaaibi SN, Waly MI, Al-Subhi L, Tageldin MH, Al-Balushi NM, Rahman MS. Ameliorative Effects of Pomegranate Peel Extract against Dietary-Induced Nonalcoholic Fatty Liver in Rats. Prev Nutr Food Sci 2016;21:14-23. [PMID: 27069901 DOI: 10.3746/pnf.2016.21.1.14] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
105 Stepanova M, Locklear T, Rafiq N, Mishra A, Venkatesan C, Younossi ZM. Long-term outcomes of heart transplant recipients with hepatitis C positivity: the data from the U.S. transplant registry. Clin Transplant 2016;30:1570-7. [DOI: 10.1111/ctr.12859] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
106 Zoppini G, Fedeli U, Gennaro N, Saugo M, Targher G, Bonora E. Mortality from chronic liver diseases in diabetes. Am J Gastroenterol. 2014;109:1020-1025. [PMID: 24890439 DOI: 10.1038/ajg.2014.132] [Cited by in Crossref: 78] [Cited by in F6Publishing: 66] [Article Influence: 11.1] [Reference Citation Analysis]
107 Wáng YXJ, Wang X, Wu P, Wang Y, Chen W, Chen H, Li J. Topics on quantitative liver magnetic resonance imaging. Quant Imaging Med Surg 2019;9:1840-90. [PMID: 31867237 DOI: 10.21037/qims.2019.09.18] [Cited by in Crossref: 9] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
108 Zhang F, Lee J, Liang S, Shum CK. Cyanobacteria blooms and non-alcoholic liver disease: evidence from a county level ecological study in the United States. Environ Health 2015;14:41. [PMID: 25948281 DOI: 10.1186/s12940-015-0026-7] [Cited by in Crossref: 51] [Cited by in F6Publishing: 36] [Article Influence: 8.5] [Reference Citation Analysis]
109 Sheldon RD, Padilla J, Jenkins NT, Laughlin MH, Rector RS. Chronic NOS inhibition accelerates NAFLD progression in an obese rat model. Am J Physiol Gastrointest Liver Physiol 2015;308:G540-9. [PMID: 25573175 DOI: 10.1152/ajpgi.00247.2014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
110 Koenig A, Stepanova M, Saab S, Ahmed A, Wong R, Younossi ZM. Long-term outcomes of lung transplant recipients with hepatitis C infection: a retrospective study of the U.S. transplant registry. Aliment Pharmacol Ther 2016;44:271-8. [DOI: 10.1111/apt.13693] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
111 Lee YH, Bang H, Park YM, Bae JC, Lee BW, Kang ES, Cha BS, Lee HC, Balkau B, Lee WY, Kim DJ. Non-laboratory-based self-assessment screening score for non-alcoholic fatty liver disease: development, validation and comparison with other scores. PLoS One 2014;9:e107584. [PMID: 25216184 DOI: 10.1371/journal.pone.0107584] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 6.4] [Reference Citation Analysis]
112 González-Rodríguez A, Mayoral R, Agra N, Valdecantos MP, Pardo V, Miquilena-Colina ME, Vargas-Castrillón J, Lo Iacono O, Corazzari M, Fimia GM. Impaired autophagic flux is associated with increased endoplasmic reticulum stress during the development of NAFLD. Cell Death Dis. 2014;5:e1179. [PMID: 24743734 DOI: 10.1038/cddis.2014.162] [Cited by in Crossref: 287] [Cited by in F6Publishing: 259] [Article Influence: 41.0] [Reference Citation Analysis]
113 Wildman-Tobriner B, Middleton MM, Moylan CA, Rossi S, Flores O, Chang ZA, Abdelmalek MF, Sirlin CB, Bashir MR. Association Between Magnetic Resonance Imaging-Proton Density Fat Fraction and Liver Histology Features in Patients With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis. Gastroenterology 2018;155:1428-1435.e2. [PMID: 30031769 DOI: 10.1053/j.gastro.2018.07.018] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 9.0] [Reference Citation Analysis]
114 Arias-Loste MT, Fábrega E, López-Hoyos M, Crespo J. The Crosstalk between Hypoxia and Innate Immunity in the Development of Obesity-Related Nonalcoholic Fatty Liver Disease. Biomed Res Int 2015;2015:319745. [PMID: 26491664 DOI: 10.1155/2015/319745] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
115 Mcpherson S, Anstee QM. Changing epidemiology of chronic liver disease among ethnic groups in the United States: McPherson and Anstee. Hepatology 2016;64:1843-6. [DOI: 10.1002/hep.28783] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
116 Mouzaki M, Wang AY, Bandsma R, Comelli EM, Arendt BM, Zhang L, Fung S, Fischer SE, McGilvray IG, Allard JP. Bile Acids and Dysbiosis in Non-Alcoholic Fatty Liver Disease. PLoS One. 2016;11:e0151829. [PMID: 27203081 DOI: 10.1371/journal.pone.0151829] [Cited by in Crossref: 167] [Cited by in F6Publishing: 154] [Article Influence: 33.4] [Reference Citation Analysis]
117 Mishra A, Otgonsuren M, Venkatesan C, Afendy M, Erario M, Younossi ZM. The inpatient economic and mortality impact of hepatocellular carcinoma from 2005 to 2009: analysis of the US nationwide inpatient sample. Liver Int 2013;33:1281-6. [PMID: 23710596 DOI: 10.1111/liv.12201] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
118 Hasse JM. Nutrition and Liver Disease: Complex Connections. Nutr Clin Pract 2013;28:12-4. [DOI: 10.1177/0884533612473156] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
119 Campisano S, La Colla A, Echarte SM, Chisari AN. Interplay between early-life malnutrition, epigenetic modulation of the immune function and liver diseases. Nutr Res Rev 2019;32:128-45. [PMID: 30707092 DOI: 10.1017/S0954422418000239] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
120 Lin Y, Shaw TG, Yang H, Lu S, Jen C, Wang L, Wong K, Chan S, Yuan Y, L'italien G, Chen C, Lee M; the R.E.V.E.A.L.-HCV Study Group. Chronic hepatitis C virus infection and the risk for diabetes: a community-based prospective study. Liver Int 2017;37:179-86. [DOI: 10.1111/liv.13194] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 5.4] [Reference Citation Analysis]
121 Loria A, Doyle K, Weinstein AA, Winter P, Escheik C, Price J, Wang L, Birerdinc A, Baranova A, Gerber L, Younossi ZM. Multiple Factors Predict Physical Performance in People with Chronic Liver Disease. American Journal of Physical Medicine & Rehabilitation 2014;93:470-6. [DOI: 10.1097/phm.0000000000000050] [Cited by in Crossref: 19] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
122 Rotman Y, Sanyal AJ. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. Gut. 2017;66:180-190. [PMID: 27646933 DOI: 10.1136/gutjnl-2016-312431] [Cited by in Crossref: 214] [Cited by in F6Publishing: 199] [Article Influence: 42.8] [Reference Citation Analysis]
123 Mitra S, De A, Chowdhury A. Epidemiology of non-alcoholic and alcoholic fatty liver diseases.Transl Gastroenterol Hepatol. 2020;5:16. [PMID: 32258520 DOI: 10.21037/tgh.2019.09.08] [Cited by in Crossref: 61] [Cited by in F6Publishing: 41] [Article Influence: 61.0] [Reference Citation Analysis]
124 Bhati C, Idowu MO, Sanyal AJ, Rivera M, Driscoll C, Stravitz RT, Kohli DR, Matherly S, Puri P, Gilles H, Cotterell A, Levy M, Sterling RK, Luketic VA, Lee H, Sharma A, Siddiqui MS. Long-term Outcomes in Patients Undergoing Liver Transplantation for Nonalcoholic Steatohepatitis-Related Cirrhosis. Transplantation. 2017;101:1867-1874. [PMID: 28296807 DOI: 10.1097/tp.0000000000001709] [Cited by in Crossref: 65] [Cited by in F6Publishing: 24] [Article Influence: 16.3] [Reference Citation Analysis]
125 Orabi D, Berger NA, Brown JM. Abnormal Metabolism in the Progression of Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma: Mechanistic Insights to Chemoprevention. Cancers (Basel) 2021;13:3473. [PMID: 34298687 DOI: 10.3390/cancers13143473] [Reference Citation Analysis]
126 Guillaume M, Moal V, Delabaudiere C, Zuberbuhler F, Robic MA, Lannes A, Metivier S, Oberti F, Gourdy P, Fouchard-Hubert I, Selves J, Michalak S, Peron JM, Cales P, Bureau C, Boursier J. Direct comparison of the specialised blood fibrosis tests FibroMeterV2G and Enhanced Liver Fibrosis score in patients with non-alcoholic fatty liver disease from tertiary care centres. Aliment Pharmacol Ther 2019;50:1214-22. [PMID: 31617224 DOI: 10.1111/apt.15529] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
127 Zhai M, Long J, Liu S, Liu C, Li L, Yang L, Li Y, Shu B. The burden of liver cirrhosis and underlying etiologies: results from the global burden of disease study 2017. Aging (Albany NY) 2021;13:279-300. [PMID: 33436531 DOI: 10.18632/aging.104127] [Reference Citation Analysis]
128 van der Windt DJ, Sud V, Zhang H, Tsung A, Huang H. The Effects of Physical Exercise on Fatty Liver Disease. Gene Expr 2018;18:89-101. [PMID: 29212576 DOI: 10.3727/105221617X15124844266408] [Cited by in Crossref: 79] [Cited by in F6Publishing: 38] [Article Influence: 19.8] [Reference Citation Analysis]
129 Safwan M, Collins KM, Abouljoud MS, Salgia R. Outcome of liver transplantation in patients with prior bariatric surgery. Liver Transpl. 2017;23:1415-1421. [PMID: 28752920 DOI: 10.1002/lt.24832] [Cited by in Crossref: 33] [Cited by in F6Publishing: 23] [Article Influence: 11.0] [Reference Citation Analysis]
130 Betrapally NS, Gillevet PM, Bajaj JS. Gut microbiome and liver disease. Transl Res. 2017;179:49-59. [PMID: 27477080 DOI: 10.1016/j.trsl.2016.07.005] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 8.6] [Reference Citation Analysis]
131 Jung JY, Shim JJ, Park SK, Ryoo JH, Choi JM, Oh IH, Jung KW, Cho H, Ki M, Won YJ, Oh CM. Serum ferritin level is associated with liver steatosis and fibrosis in Korean general population. Hepatol Int 2019;13:222-33. [PMID: 30182166 DOI: 10.1007/s12072-018-9892-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
132 BasuRay S, Wang Y, Smagris E, Cohen JC, Hobbs HH. Accumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis. Proc Natl Acad Sci U S A 2019;116:9521-6. [PMID: 31019090 DOI: 10.1073/pnas.1901974116] [Cited by in Crossref: 81] [Cited by in F6Publishing: 71] [Article Influence: 40.5] [Reference Citation Analysis]
133 Poovorawan K, Treeprasertsuk S, Thepsuthammarat K, Wilairatana P, Kitsahawong B, Phaosawasdi K. The burden of cirrhosis and impact of universal coverage public health care system in Thailand: Nationwide study. Ann Hepatol 2015;14:862-8. [PMID: 26436358 DOI: 10.5604/16652681.1171773] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
134 Wong RJ, Liu B, Bhuket T. Significant burden of nonalcoholic fatty liver disease with advanced fibrosis in the US: a cross-sectional analysis of 2011-2014 National Health and Nutrition Examination Survey. Aliment Pharmacol Ther. 2017;46:974-980. [PMID: 28914448 DOI: 10.1111/apt.14327] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 12.5] [Reference Citation Analysis]
135 Best LM, Leung J, Freeman SC, Sutton AJ, Cooper NJ, Milne EJ, Cowlin M, Payne A, Walshaw D, Thorburn D, Pavlov CS, Davidson BR, Tsochatzis E, Williams NR, Gurusamy KS. Induction immunosuppression in adults undergoing liver transplantation: a network meta-analysis. Cochrane Database Syst Rev 2020;1:CD013203. [PMID: 31978255 DOI: 10.1002/14651858.CD013203.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
136 Zhan C, Olsen S, Zhang HC, Kannengiesser S, Chandarana H, Shanbhogue KP. Detection of hepatic steatosis and iron content at 3 Tesla: comparison of two-point Dixon, quantitative multi-echo Dixon, and MR spectroscopy. Abdom Radiol (NY). 2019;44:3040-3048. [PMID: 31286208 DOI: 10.1007/s00261-019-02118-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
137 Matetic A, Contractor T, Mohamed MO, Bhardwaj R, Aneja A, Myint PK, Rakoski MO, Zieroth S, Paul TK, Mamas MA. Trends, management and outcomes of acute myocardial infarction in chronic liver disease. Int J Clin Pract 2021;75:e13841. [PMID: 33220158 DOI: 10.1111/ijcp.13841] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
138 Srinivasa S, Fitch KV, Quadri N, Maehler P, O'Malley TK, Martinez-Salazar EL, Burdo TH, Feldpausch M, Torriani M, Adler GK, Grinspoon SK. Significant Association of Aldosterone and Liver Fat Among HIV-Infected Individuals With Metabolic Dysregulation. J Endocr Soc 2018;2:1147-57. [PMID: 30283827 DOI: 10.1210/js.2018-00194] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
139 Zhang X, Heredia NI, Balakrishnan M, Thrift AP. Prevalence and factors associated with NAFLD detected by vibration controlled transient elastography among US adults: Results from NHANES 2017-2018. PLoS One 2021;16:e0252164. [PMID: 34081733 DOI: 10.1371/journal.pone.0252164] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
140 Boyle M, Masson S, Anstee QM. The bidirectional impacts of alcohol consumption and the metabolic syndrome: Cofactors for progressive fatty liver disease. Journal of Hepatology 2018;68:251-67. [DOI: 10.1016/j.jhep.2017.11.006] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 17.3] [Reference Citation Analysis]
141 Wang S, Zhang C, Zhang G, Yuan Z, Liu Y, Ding L, Sun X, Jia H, Xue F. Association between white blood cell count and non-alcoholic fatty liver disease in urban Han Chinese: a prospective cohort study. BMJ Open 2016;6:e010342. [PMID: 27251683 DOI: 10.1136/bmjopen-2015-010342] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
142 Purvis LAB, Clarke WT, Valkovič L, Levick C, Pavlides M, Barnes E, Cobbold JF, Robson MD, Rodgers CT. Phosphodiester content measured in human liver by in vivo 31 P MR spectroscopy at 7 tesla. Magn Reson Med 2017;78:2095-105. [PMID: 28244131 DOI: 10.1002/mrm.26635] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
143 Malnick S, Maor Y. The Interplay between Alcoholic Liver Disease, Obesity, and the Metabolic Syndrome. Visc Med 2020;36:198-205. [PMID: 32775350 DOI: 10.1159/000507233] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
144 Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, Qiu Y, Burns L, Afendy A, Nader F. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol. 2019;71:793-801. [PMID: 31279902 DOI: 10.1016/j.jhep.2019.06.021] [Cited by in Crossref: 295] [Cited by in F6Publishing: 248] [Article Influence: 147.5] [Reference Citation Analysis]
145 Danford CJ, Sanchez JE, Corey KE. Managing the Burden of Non-NASH NAFLD. Curr Hepatol Rep 2017;16:326-34. [PMID: 29503789 DOI: 10.1007/s11901-017-0371-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
146 Boursier J, Tsochatzis EA. Case-finding strategies in non-alcoholic fatty liver disease. JHEP Rep 2021;3:100219. [PMID: 33659890 DOI: 10.1016/j.jhepr.2020.100219] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
147 Athyros VG, Tziomalos K, Katsiki N, Doumas M, Karagiannis A, Mikhailidis DP. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. World J Gastroenterol. 2015;21:6820-6834. [PMID: 26078558 DOI: 10.3748/wjg.v21.i22.6820] [Cited by in CrossRef: 88] [Cited by in F6Publishing: 76] [Article Influence: 17.6] [Reference Citation Analysis]
148 Farooque U, Lohano AK, Dahri Q, Arain N, Farukhuddin F, Khadke C, Prince F, Farooque R, Shehata MA, Bin Zafar MD. The Pattern of Dyslipidemia in Chronic Liver Disease Patients. Cureus 2021;13:e13259. [PMID: 33728198 DOI: 10.7759/cureus.13259] [Reference Citation Analysis]
149 Konerman MA, Loomba R. Editorial: the burden and aetiology of liver cirrhosis, and the risk of death. Aliment Pharmacol Ther 2016;44:202-3. [PMID: 27296684 DOI: 10.1111/apt.13658] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
150 Ruhanen H, Perttilä J, Hölttä-Vuori M, Zhou Y, Yki-Järvinen H, Ikonen E, Käkelä R, Olkkonen VM. PNPLA3 mediates hepatocyte triacylglycerol remodeling. J Lipid Res 2014;55:739-46. [PMID: 24511104 DOI: 10.1194/jlr.M046607] [Cited by in Crossref: 79] [Cited by in F6Publishing: 41] [Article Influence: 11.3] [Reference Citation Analysis]
151 Shanmugam H, Di Ciaula A, Di Palo DM, Molina-Molina E, Garruti G, Faienza MF, vanErpecum K, Portincasa P. Multiplying effects of COVID-19 lockdown on metabolic risk and fatty liver. Eur J Clin Invest 2021;51:e13597. [PMID: 34032283 DOI: 10.1111/eci.13597] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
152 Medici V, Halsted CH. Folate, alcohol, and liver disease. Mol Nutr Food Res. 2013;57:596-606. [PMID: 23136133 DOI: 10.1002/mnfr.201200077] [Cited by in Crossref: 57] [Cited by in F6Publishing: 41] [Article Influence: 6.3] [Reference Citation Analysis]
153 Lamos EM, Kristan M, Siamashvili M, Davis SN. Effects of anti-diabetic treatments in type 2 diabetes and fatty liver disease. Expert Rev Clin Pharmacol 2021;14:837-52. [PMID: 33882758 DOI: 10.1080/17512433.2021.1917374] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
154 Singh L, Joshi T, Tewari D, Echeverría J, Mocan A, Sah AN, Parvanov E, Tzvetkov NT, Ma ZF, Lee YY, Poznański P, Huminiecki L, Sacharczuk M, Jóźwik A, Horbańczuk JO, Feder-Kubis J, Atanasov AG. Ethnopharmacological Applications Targeting Alcohol Abuse: Overview and Outlook. Front Pharmacol 2019;10:1593. [PMID: 32116660 DOI: 10.3389/fphar.2019.01593] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
155 Bettermann K, Hohensee T, Haybaeck J. Steatosis and steatohepatitis: complex disorders. Int J Mol Sci. 2014;15:9924-9944. [PMID: 24897026 DOI: 10.3390/ijms15069924] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
156 A-Kader HH. Lysosomal acid lipase deficiency: a form of non-obese fatty liver disease (NOFLD). Expert Rev Gastroenterol Hepatol 2017;11:911-24. [PMID: 28612634 DOI: 10.1080/17474124.2017.1343144] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
157 Nagpal SJ, Kabbany MN, Mohamad B, Lopez R, Zein NN, Alkhouri N. Portal Hypertension Complications Are Frequently the First Presentation of NAFLD in Patients Undergoing Liver Transplantation Evaluation. Dig Dis Sci 2016;61:2102-7. [PMID: 26993824 DOI: 10.1007/s10620-016-4124-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
158 Sayari S, Neishaboori H, Jameshorani M. Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease. Clin Mol Hepatol 2018;24:331-8. [PMID: 29890569 DOI: 10.3350/cmh.2018.0006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
159 Kehagias D, Mulita F, Drakos N, Seretis F, Liolis E, Kehagias I. Bariatric surgery: blessing or sometimes curse for the liver? Prz Menopauzalny 2021;20:108-11. [PMID: 34321990 DOI: 10.5114/pm.2021.106062] [Reference Citation Analysis]
160 Xia MF, Yki-Järvinen H, Bian H, Lin HD, Yan HM, Chang XX, Zhou Y, Gao X. Influence of Ethnicity on the Accuracy of Non-Invasive Scores Predicting Non-Alcoholic Fatty Liver Disease. PLoS One 2016;11:e0160526. [PMID: 27579785 DOI: 10.1371/journal.pone.0160526] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
161 Jalili R, Somi MH, Hosseinifard H, Salehnia F, Ghojazadeh M, Makhdami N, Shirmohammadi M. The Evaluation of Effective Drugs for the Treatment of Non-Alcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis. Adv Pharm Bull. 2020;10:542-555. [PMID: 33072533 DOI: 10.34172/apb.2020.065] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
162 Sun C, Liu X, Yi Z, Xiao X, Yang M, Hu G, Liu H, Liao L, Huang F. Genome-wide analysis of long noncoding RNA expression profiles in patients with non-alcoholic fatty liver disease. IUBMB Life 2015;67:847-52. [PMID: 26472541 DOI: 10.1002/iub.1442] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 5.8] [Reference Citation Analysis]
163 Younossi ZM, Stepanova M. Changes in hepatitis A and B vaccination rates in adult patients with chronic liver diseases and diabetes in the U.S. population. Hepatology 2011;54:1167-78. [DOI: 10.1002/hep.24510] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
164 Nelsen EM, Newman DB, Sweetser S. 52-year-old man with liver enzyme abnormalities and elevated ferritin level. Mayo Clin Proc 2012;87:94-7. [PMID: 22212974 DOI: 10.1016/j.mayocp.2011.08.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
165 Younossi ZM, Stepanova M, Saab S, Kalwaney S, Clement S, Henry L, Frost S, Hunt S. The impact of type 2 diabetes and obesity on the long-term outcomes of more than 85 000 liver transplant recipients in the US. Aliment Pharmacol Ther. 2014;40:686-694. [PMID: 25040315 DOI: 10.1111/apt.12881] [Cited by in Crossref: 53] [Cited by in F6Publishing: 44] [Article Influence: 7.6] [Reference Citation Analysis]
166 Clemens RA, Jones JM, Kern M, Lee S, Mayhew EJ, Slavin JL, Zivanovic S. Functionality of Sugars in Foods and Health: Functionality of sugars…. COMPREHENSIVE REVIEWS IN FOOD SCIENCE AND FOOD SAFETY 2016;15:433-70. [DOI: 10.1111/1541-4337.12194] [Cited by in Crossref: 73] [Cited by in F6Publishing: 20] [Article Influence: 14.6] [Reference Citation Analysis]
167 Wang L, Guo J, Lu J. Risk factor compositions of nonalcoholic fatty liver disease change with body mass index in males and females. Oncotarget 2016;7:35632-42. [PMID: 27248665 DOI: 10.18632/oncotarget.9691] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
168 Benotti P, Wood GC, Argyropoulos G, Pack A, Keenan BT, Gao X, Gerhard G, Still C. The impact of obstructive sleep apnea on nonalcoholic fatty liver disease in patients with severe obesity. Obesity (Silver Spring). 2016;24:871-877. [PMID: 26880657 DOI: 10.1002/oby.21409] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
169 Motamedi MAK, Khalaj A, Mahdavi M, Valizadeh M, Hosseinpanah F, Barzin M. Longitudinal Comparison of the Effect of Gastric Bypass to Sleeve Gastrectomy on Liver Function in a Bariatric Cohort: Tehran Obesity Treatment Study (TOTS). Obes Surg 2019;29:511-8. [PMID: 30298459 DOI: 10.1007/s11695-018-3537-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
170 Su X, Xu J, Zheng C. The relationship between non-alcoholic fatty liver and skeletal muscle mass to visceral fat area ratio in women with type 2 diabetes. BMC Endocr Disord 2019;19:76. [PMID: 31315613 DOI: 10.1186/s12902-019-0404-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
171 Guglielmo FF, Venkatesh SK, Mitchell DG. Liver MR Elastography Technique and Image Interpretation: Pearls and Pitfalls. RadioGraphics 2019;39:1983-2002. [DOI: 10.1148/rg.2019190034] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
172 Leitão HS, Doblas S, Garteiser P, d'Assignies G, Paradis V, Mouri F, Geraldes CF, Ronot M, Van Beers BE. Hepatic Fibrosis, Inflammation, and Steatosis: Influence on the MR Viscoelastic and Diffusion Parameters in Patients with Chronic Liver Disease. Radiology 2017;283:98-107. [PMID: 27788034 DOI: 10.1148/radiol.2016151570] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 6.2] [Reference Citation Analysis]
173 Yang JD, Abdelmalek MF, Pang H, Guy CD, Smith AD, Diehl AM, Suzuki A. Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis. Hepatology. 2014;59:1406-1414. [PMID: 24123276 DOI: 10.1002/hep.26761] [Cited by in Crossref: 143] [Cited by in F6Publishing: 121] [Article Influence: 20.4] [Reference Citation Analysis]
174 Tziomalos K, Giampatzis V, Bouziana SD, Spanou M, Papadopoulou M, Pavlidis A, Kostaki S, Bozikas A, Savopoulos C, Hatzitolios AI. Association between nonalcoholic fatty liver disease and acute ischemic stroke severity and outcome. World J Hepatol. 2013;5:621-626. [PMID: 24303090 DOI: 10.4254/wjh.v5.i11.621] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
175 Wang Y, Zeng Y, Lin C, Chen Z. Hypertension and non-alcoholic fatty liver disease proven by transient elastography: Hypertension and NAFLD. Hepatol Res 2016;46:1304-10. [DOI: 10.1111/hepr.12688] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
176 Patel SS, Siddiqui MS. Current and Emerging Therapies for Non-alcoholic Fatty Liver Disease. Drugs. 2019;79:75-84. [PMID: 30588564 DOI: 10.1007/s40265-018-1040-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
177 Alexopoulos AS, Crowley MJ, Wang Y, Moylan CA, Guy CD, Henao R, Piercy DL, Seymour KA, Sudan R, Portenier DD, Diehl AM, Coviello AD, Abdelmalek MF. Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease. Hepatology 2021. [PMID: 33724511 DOI: 10.1002/hep.31806] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
178 Kennedy P, Wagner M, Castéra L, Hong CW, Johnson CL, Sirlin CB, Taouli B. Quantitative Elastography Methods in Liver Disease: Current Evidence and Future Directions. Radiology 2018;286:738-63. [PMID: 29461949 DOI: 10.1148/radiol.2018170601] [Cited by in Crossref: 119] [Cited by in F6Publishing: 91] [Article Influence: 39.7] [Reference Citation Analysis]
179 Bessone F, Razori MV, Roma MG. Molecular pathways of nonalcoholic fatty liver disease development and progression. Cell Mol Life Sci. 2019;76:99-128. [PMID: 30343320 DOI: 10.1007/s00018-018-2947-0] [Cited by in Crossref: 109] [Cited by in F6Publishing: 100] [Article Influence: 36.3] [Reference Citation Analysis]
180 Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328-357. [PMID: 28714183 DOI: 10.1002/hep.29367] [Cited by in Crossref: 1978] [Cited by in F6Publishing: 1578] [Article Influence: 494.5] [Reference Citation Analysis]
181 Robinson KE, Shah VH. Pathogenesis and pathways: nonalcoholic fatty liver disease & alcoholic liver disease. Transl Gastroenterol Hepatol 2020;5:49. [PMID: 33073044 DOI: 10.21037/tgh.2019.12.05] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
182 Cantoral A, Contreras-Manzano A, Luna-Villa L, Batis C, Roldán-Valadez EA, Ettinger AS, Mercado A, Peterson KE, Téllez-Rojo MM, Rivera JA. Dietary Sources of Fructose and Its Association with Fatty Liver in Mexican Young Adults. Nutrients 2019;11:E522. [PMID: 30823422 DOI: 10.3390/nu11030522] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
183 Han B, Wang J, Yang W, Chen X, Wang H, Chen J, Zhang C, Sun J, Wei X. Hydrothermal synthesis of flower-like In2O3 as a chemiresistive isoprene sensor for breath analysis. Sensors and Actuators B: Chemical 2020;309:127788. [DOI: 10.1016/j.snb.2020.127788] [Cited by in Crossref: 17] [Cited by in F6Publishing: 1] [Article Influence: 17.0] [Reference Citation Analysis]
184 Yoshii D, Nakagawa T, Komohara Y, Kawaguchi H, Yamada S, Tanimoto A. Phenotypic Changes in Macrophage Activation in a Model of Nonalcoholic Fatty Liver Disease using Microminipigs. J Atheroscler Thromb 2021;28:844-51. [PMID: 33012740 DOI: 10.5551/jat.57703] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
185 Teschke R. Alcoholic steatohepatitis (ASH) and alcoholic hepatitis (AH): cascade of events, clinical aspects, and pharmacotherapy options. Expert Opin Pharmacother 2018;19:779-93. [PMID: 29708448 DOI: 10.1080/14656566.2018.1465929] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
186 Younossi ZM, Stepanova M, Negro F, Hallaji S, Younossi Y, Lam B, Srishord M. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine (Baltimore). 2012;91:319-327. [PMID: 23117851 DOI: 10.1097/md.0b013e3182779d49] [Cited by in Crossref: 280] [Cited by in F6Publishing: 132] [Article Influence: 35.0] [Reference Citation Analysis]
187 Chen L, Huang P, Chien C, Lin C, Chien R. A community-based study on the application of fatty liver index in screening subjects with nonalcoholic fatty liver disease. Journal of the Formosan Medical Association 2020;119:173-81. [DOI: 10.1016/j.jfma.2019.03.016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
188 Leung C, Yeoh SW, Patrick D, Ket S, Marion K, Gow P, Angus PW. Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-alcoholic fatty liver disease. World J Gastroenterol. 2015;21:1189-1196. [PMID: 25632192 DOI: 10.3748/wjg.v21.i4.1189] [Cited by in CrossRef: 66] [Cited by in F6Publishing: 58] [Article Influence: 11.0] [Reference Citation Analysis]
189 Hyötyläinen T, Jerby L, Petäjä EM, Mattila I, Jäntti S, Auvinen P, Gastaldelli A, Yki-Järvinen H, Ruppin E, Orešič M. Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease. Nat Commun 2016;7:8994. [PMID: 26839171 DOI: 10.1038/ncomms9994] [Cited by in Crossref: 67] [Cited by in F6Publishing: 58] [Article Influence: 13.4] [Reference Citation Analysis]
190 Montomoli J, Erichsen R, Gammelager H, Pedersen AB. Liver disease and mortality among patients with hip fracture: a population-based cohort study. Clin Epidemiol 2018;10:991-1000. [PMID: 30174458 DOI: 10.2147/CLEP.S168237] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
191 Orman ES, Roberts A, Ghabril M, Nephew L, Desai AP, Patidar K, Chalasani N. Trends in Characteristics, Mortality, and Other Outcomes of Patients With Newly Diagnosed Cirrhosis. JAMA Netw Open 2019;2:e196412. [PMID: 31251379 DOI: 10.1001/jamanetworkopen.2019.6412] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
192 Basu Ray S. PNPLA3-I148M: a problem of plenty in non-alcoholic fatty liver disease. Adipocyte 2019;8:201-8. [PMID: 31062641 DOI: 10.1080/21623945.2019.1607423] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
193 Li X, Yuan FL. Comment on "Gut Microbiota as a Driver of Inflammation in Nonalcoholic Fatty Liver Disease". Mediators Inflamm 2018;2018:3746509. [PMID: 30116145 DOI: 10.1155/2018/3746509] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
194 Byrd KK, Mehal JM, Schillie SF, Holman RC, Haberling D, Murphy T. Chronic Liver Disease-Associated Hospitalizations Among Adults with Diabetes, National Inpatient Sample, 2001-2012. Public Health Rep 2015;130:693-703. [PMID: 26556941 DOI: 10.1177/003335491513000619] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
195 Hanson A, Wilhelmsen D, DiStefano JK. The Role of Long Non-Coding RNAs (lncRNAs) in the Development and Progression of Fibrosis Associated with Nonalcoholic Fatty Liver Disease (NAFLD). Noncoding RNA 2018;4:E18. [PMID: 30134610 DOI: 10.3390/ncrna4030018] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
196 Greuter T, Malhi H, Gores GJ, Shah VH. Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis. JCI Insight 2017;2:95354. [PMID: 28878132 DOI: 10.1172/jci.insight.95354] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
197 Gerstenmaier JF, Gibson RN. Ultrasound in chronic liver disease. Insights Imaging 2014;5:441-55. [PMID: 24859758 DOI: 10.1007/s13244-014-0336-2] [Cited by in Crossref: 48] [Cited by in F6Publishing: 32] [Article Influence: 6.9] [Reference Citation Analysis]
198 Sayiner M, Younossi ZM. Nonalcoholic Steatohepatitis Is Becoming a Top Indication for Liver Transplantation Worldwide. Liver Transpl 2019;25:10-1. [PMID: 30472779 DOI: 10.1002/lt.25387] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
199 Botello-Manilla AE, López-Sánchez GN, Chávez-Tapia NC, Uribe M, Nuño-Lámbarri N. Hepatic steatosis and respiratory diseases: a new panorama. Ann Hepatol 2021;24:100320. [PMID: 33549735 DOI: 10.1016/j.aohep.2021.100320] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
200 Schlansky B, Naugler WE, Orloff SL, Enestvedt CK. Higher Mortality and Survival Benefit in Obese Patients Awaiting Liver Transplantation. Transplantation. 2016;100:2648-2655. [PMID: 27575690 DOI: 10.1097/tp.0000000000001461] [Cited by in Crossref: 27] [Cited by in F6Publishing: 8] [Article Influence: 6.8] [Reference Citation Analysis]
201 Teschke R, Danan G. Drug-induced liver injury: Is chronic liver disease a risk factor and a clinical issue? Expert Opin Drug Metab Toxicol. 2017;13:425-438. [PMID: 27822971 DOI: 10.1080/17425255.2017.1252749] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 6.4] [Reference Citation Analysis]
202 Jung JY, Park SK, Ryoo J, Oh C, Kang JG, Lee J, Choi J. Effect of non-alcoholic fatty liver disease on left ventricular diastolic function and geometry in the Korean general population: NAFLD, left ventricular diastolic dysfunction. Hepatol Res 2017;47:522-32. [DOI: 10.1111/hepr.12770] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
203 Hajifathalian K, Mehta A, Ang B, Skaf D, Shah SL, Saumoy M, Dawod Q, Dawod E, Shukla A, Aronne L, Brown RS, Cohen DE, Dannenberg AJ, Fortune B, Kumar S, Sharaiha RZ. Improvement in insulin resistance and estimated hepatic steatosis and fibrosis after endoscopic sleeve gastroplasty. Gastrointest Endosc 2021;93:1110-8. [PMID: 32861753 DOI: 10.1016/j.gie.2020.08.023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
204 Yang BL, Wu WC, Fang KC, Wang YC, Huo TI, Huang YH, Yang HI, Su CW, Lin HC, Lee FY, Wu JC, Lee SD. External validation of fatty liver index for identifying ultrasonographic fatty liver in a large-scale cross-sectional study in Taiwan. PLoS One 2015;10:e0120443. [PMID: 25781622 DOI: 10.1371/journal.pone.0120443] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 8.3] [Reference Citation Analysis]
205 Laursen TL, Hagemann CA, Wei C, Kazankov K, Thomsen KL, Knop FK, Grønbæk H. Bariatric surgery in patients with non-alcoholic fatty liver disease - from pathophysiology to clinical effects. World J Hepatol 2019;11:138-49. [PMID: 30820265 DOI: 10.4254/wjh.v11.i2.138] [Cited by in Crossref: 61] [Cited by in F6Publishing: 46] [Article Influence: 30.5] [Reference Citation Analysis]
206 Polyzos SA, Kountouras J, Mantzoros CS. Sulfated oxysterols as candidates for the treatment of nonalcoholic fatty liver disease. Metabolism 2012;61:755-8. [PMID: 22386938 DOI: 10.1016/j.metabol.2012.01.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
207 Cheng YL, Wang YJ, Kao WY, Chen PH, Huo TI, Huang YH, Lan KH, Su CW, Chan WL, Lin HC, Lee FY, Wu JC. Inverse association between hepatitis B virus infection and fatty liver disease: a large-scale study in populations seeking for check-up. PLoS One. 2013;8:e72049. [PMID: 23991037 DOI: 10.1371/journal.pone.0072049] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 6.1] [Reference Citation Analysis]
208 Mueller NT, Pereira MA, Demerath EW, Dreyfus JG, MacLehose RF, Carr JJ, Terry JG, Jacobs DR Jr. Earlier menarche is associated with fatty liver and abdominal ectopic fat in midlife, independent of young adult BMI: The CARDIA study. Obesity (Silver Spring) 2015;23:468-74. [PMID: 25521620 DOI: 10.1002/oby.20950] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
209 Setiawan VW, Porcel J, Wei P, Stram DO, Noureddin N, Lu SC, Le Marchand L, Noureddin M. Coffee Drinking and Alcoholic and Nonalcoholic Fatty Liver Diseases and Viral Hepatitis in the Multiethnic Cohort. Clin Gastroenterol Hepatol 2017;15:1305-7. [PMID: 28300689 DOI: 10.1016/j.cgh.2017.02.038] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
210 Teschke R, Wolff A, Eickhoff A, Danan G. Is obesity rather than the dietary supplement used for weight reduction the cause of liver injury? JGH Open 2018;2:152-7. [PMID: 30483581 DOI: 10.1002/jgh3.12057] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
211 Simeone JC, Bae JP, Hoogwerf BJ, Li Q, Haupt A, Ali AK, Boardman MK, Nordstrom BL. Clinical course of nonalcoholic fatty liver disease: an assessment of severity, progression, and outcomes. Clin Epidemiol 2017;9:679-88. [PMID: 29276410 DOI: 10.2147/CLEP.S144368] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
212 Teschke R, Danan G. Drug induced liver injury with analysis of alternative causes as confounding variables. Br J Clin Pharmacol 2018;84:1467-77. [PMID: 29607530 DOI: 10.1111/bcp.13593] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 10.0] [Reference Citation Analysis]
213 Atarashi M, Izawa T, Miyagi R, Ohji S, Hashimoto A, Kuwamura M, Yamate J. Dietary Iron Supplementation Alters Hepatic Inflammation in a Rat Model of Nonalcoholic Steatohepatitis. Nutrients 2018;10:E175. [PMID: 29401710 DOI: 10.3390/nu10020175] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
214 Lugoboni F, Mirijello A, Morbioli L, Faccini M, Casari R, De Cosmo S, Gasbarrini A, Addolorato G. Zolpidem high-dose abuse: what about the liver? Results from a series of 107 patients. Expert Opinion on Drug Safety 2019;18:753-8. [DOI: 10.1080/14740338.2019.1628216] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
215 Uhlig J, Sellers CM, Cha C, Khan SA, Lacy J, Stein SM, Kim HS. Intrahepatic Cholangiocarcinoma: Socioeconomic Discrepancies, Contemporary Treatment Approaches and Survival Trends from the National Cancer Database. Ann Surg Oncol 2019;26:1993-2000. [PMID: 30693451 DOI: 10.1245/s10434-019-07175-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
216 Kechagias S, Nasr P, Blomdahl J, Ekstedt M. Established and emerging factors affecting the progression of nonalcoholic fatty liver disease. Metabolism 2020;111S:154183. [PMID: 32061907 DOI: 10.1016/j.metabol.2020.154183] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 14.0] [Reference Citation Analysis]
217 Zhang QQ, Lu LG. Nonalcoholic Fatty Liver Disease: Dyslipidemia, Risk for Cardiovascular Complications, and Treatment Strategy. J Clin Transl Hepatol 2015;3:78-84. [PMID: 26357637 DOI: 10.14218/JCTH.2014.00037] [Cited by in Crossref: 41] [Cited by in F6Publishing: 24] [Article Influence: 6.8] [Reference Citation Analysis]
218 Kim HS, El-Serag HB. The Epidemiology of Hepatocellular Carcinoma in the USA. Curr Gastroenterol Rep. 2019;21:17. [PMID: 30976932 DOI: 10.1007/s11894-019-0681-x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 18.5] [Reference Citation Analysis]
219 Yilmaz B, Sahin K, Bilen H, Bahcecioglu IH, Bilir B, Ashraf S, Halazun KJ, Kucuk O. Carotenoids and non-alcoholic fatty liver disease. Hepatobiliary Surg Nutr. 2015;4:161-171. [PMID: 26151056 DOI: 10.3978/j.issn.2304-3881.2015.01.11] [Cited by in F6Publishing: 23] [Reference Citation Analysis]
220 Adams LA. Mortality in nonalcoholic fatty liver disease: Clues from the cremona study. Hepatology 2011;54:6-8. [DOI: 10.1002/hep.24445] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
221 Batman B, Altun H, Simsek B, Aslan E, Namli Koc S. The Effect of Laparoscopic Sleeve Gastrectomy on Nonalcoholic Fatty Liver Disease. Surg Laparosc Endosc Percutan Tech 2019;29:509-12. [PMID: 31107849 DOI: 10.1097/SLE.0000000000000672] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
222 Goh GB, Schauer PR, McCullough AJ. Considerations for bariatric surgery in patients with cirrhosis. World J Gastroenterol 2018;24:3112-9. [PMID: 30065557 DOI: 10.3748/wjg.v24.i28.3112] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 22] [Article Influence: 9.3] [Reference Citation Analysis]
223 Carbone LJ, Angus PW, Yeomans ND. Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2016;31:23-31. [PMID: 26111358 DOI: 10.1111/jgh.13026] [Cited by in Crossref: 53] [Cited by in F6Publishing: 43] [Article Influence: 10.6] [Reference Citation Analysis]
224 Olefson S, Jackson M, Grand DJ, Charpentier KP, Makwana N, Promrat K. Identification of Nonalcoholic Fatty Liver Disease following Pancreatic Surgery in a Western Cohort Using a Novel Radiographic Technique. J Clin Transl Hepatol 2015;3:246-53. [PMID: 26807379 DOI: 10.14218/JCTH.2015.00029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
225 Kumar R, Priyadarshi RN, Anand U. Non-alcoholic Fatty Liver Disease: Growing Burden, Adverse Outcomes and Associations. J Clin Transl Hepatol 2020;8:76-86. [PMID: 32274348 DOI: 10.14218/JCTH.2019.00051] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
226 Wright AP, Desai AP, Bajpai S, King LY, Sahani DV, Corey KE. Gaps in recognition and evaluation of incidentally identified hepatic steatosis. Dig Dis Sci 2015;60:333-8. [PMID: 25190263 DOI: 10.1007/s10620-014-3346-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
227 Liu K, Mccaughan GW. Epidemiology and Etiologic Associations of Non-alcoholic Fatty Liver Disease and Associated HCC. In: Yu J, editor. Obesity, Fatty Liver and Liver Cancer. Singapore: Springer; 2018. pp. 3-18. [DOI: 10.1007/978-981-10-8684-7_2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
228 Kardashian A, Ma Y, Scherzer R, Price JC, Sarkar M, Korn N, Tillinghast K, Peters MG, Noworolski SM, Tien PC. Sex differences in the association of HIV infection with hepatic steatosis. AIDS 2017;31:365-73. [PMID: 27831949 DOI: 10.1097/QAD.0000000000001334] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 3.7] [Reference Citation Analysis]
229 Hagström H, Stål P, Hultcrantz R, Hemmingsson T, Andreasson A. Overweight in late adolescence predicts development of severe liver disease later in life: A 39years follow-up study. Journal of Hepatology 2016;65:363-8. [DOI: 10.1016/j.jhep.2016.03.019] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 8.8] [Reference Citation Analysis]
230 Lorenzo C, Hanley AJ, Rewers MJ, Haffner SM. The association of alanine aminotransferase within the normal and mildly elevated range with lipoproteins and apolipoproteins: the Insulin Resistance Atherosclerosis Study. Diabetologia 2013;56:746-57. [PMID: 23344727 DOI: 10.1007/s00125-012-2826-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
231 Younossi ZM. Non-alcoholic fatty liver disease – A global public health perspective. Journal of Hepatology 2019;70:531-44. [DOI: 10.1016/j.jhep.2018.10.033] [Cited by in Crossref: 452] [Cited by in F6Publishing: 364] [Article Influence: 226.0] [Reference Citation Analysis]
232 Weiß J, Rau M, Geier A. Non-alcoholic fatty liver disease: epidemiology, clinical course, investigation, and treatment. Dtsch Arztebl Int 2014;111:447-52. [PMID: 25019921 DOI: 10.3238/arztebl.2014.0447] [Cited by in Crossref: 19] [Cited by in F6Publishing: 39] [Article Influence: 3.2] [Reference Citation Analysis]
233 Reddy SK, Hyder O, Marsh JW, Sotiropoulos GC, Paul A, Alexandrescu S, Marques H, Pulitano C, Barroso E, Aldrighetti L. Prevalence of nonalcoholic steatohepatitis among patients with resectable intrahepatic cholangiocarcinoma. J Gastrointest Surg. 2013;17:748-755. [PMID: 23355033 DOI: 10.1007/s11605-013-2149-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
234 Lin QC, Chen LD, Chen GP, Zhao JM, Chen X, Huang JF, Wu LH. Association between nocturnal hypoxia and liver injury in the setting of nonalcoholic fatty liver disease. Sleep Breath 2015;19:273-80. [PMID: 24870112 DOI: 10.1007/s11325-014-1008-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
235 Reddy SK, Reilly C, Zhan M, Mindikoglu AL, Jiang Y, Lane BF, Alexander HR, Culpepper WJ, El-Kamary SS. Long-term influence of chemotherapy on steatosis-associated advanced hepatic fibrosis. Med Oncol 2014;31:971. [PMID: 24798875 DOI: 10.1007/s12032-014-0971-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
236 Loy VM, Joyce C, Bello S, Vonroenn N, Cotler SJ. Gender disparities in liver transplant candidates with nonalcoholic steatohepatitis. Clin Transplant 2018;32:e13297. [DOI: 10.1111/ctr.13297] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
237 Ruhl CE, Everhart JE. Fatty liver indices in the multiethnic United States National Health and Nutrition Examination Survey. Aliment Pharmacol Ther. 2015;41:65-76. [PMID: 25376360 DOI: 10.1111/apt.13012] [Cited by in Crossref: 110] [Cited by in F6Publishing: 97] [Article Influence: 15.7] [Reference Citation Analysis]
238 Acharya C, Sahingur SE, Bajaj JS. Microbiota, cirrhosis, and the emerging oral-gut-liver axis. JCI Insight. 2017;2:e94416. [PMID: 28978799 DOI: 10.1172/jci.insight.94416] [Cited by in Crossref: 72] [Cited by in F6Publishing: 57] [Article Influence: 18.0] [Reference Citation Analysis]
239 Wijarnpreecha K, Thongprayoon C, Panjawatanan P, Ungprasert P. Short sleep duration and risk of nonalcoholic fatty liver disease: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2016;31:1802-1807. [PMID: 27029776 DOI: 10.1111/jgh.13391] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
240 Blake L, Duarte RV, Cummins C. Decision analytic model of the diagnostic pathways for patients with suspected non-alcoholic fatty liver disease using non-invasive transient elastography and multiparametric magnetic resonance imaging. BMJ Open 2016;6:e010507. [PMID: 27650757 DOI: 10.1136/bmjopen-2015-010507] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
241 Sheldon RD, Nicole Blaize A, Fletcher JA, Pearson KJ, Donkin SS, Newcomer SC, Rector RS. Gestational exercise protects adult male offspring from high-fat diet-induced hepatic steatosis. J Hepatol 2016;64:171-8. [PMID: 26325536 DOI: 10.1016/j.jhep.2015.08.022] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
242 Amirkalali B, Sohrabi MR, Esrafily A, Jalali M, Gholami A, Hosseinzadeh P, Keyvani H, Shidfar F, Zamani F. Association between Nicotinamide Phosphoribosyltransferase and de novo Lipogenesis in Nonalcoholic Fatty Liver Disease. Med Princ Pract 2017;26:251-7. [PMID: 28092906 DOI: 10.1159/000455862] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
243 Koola JD, Davis SE, Al-Nimri O, Parr SK, Fabbri D, Malin BA, Ho SB, Matheny ME. Development of an automated phenotyping algorithm for hepatorenal syndrome. J Biomed Inform 2018;80:87-95. [PMID: 29530803 DOI: 10.1016/j.jbi.2018.03.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
244 Kleiner DE, Berk PD, Hsu JY, Courcoulas AP, Flum D, Khandelwal S, Pender J, Pomp A, Roerig J, Machado LL, Wolfe BM, Belle SH; LABS Consortium. Hepatic pathology among patients without known liver disease undergoing bariatric surgery: observations and a perspective from the longitudinal assessment of bariatric surgery (LABS) study. Semin Liver Dis 2014;34:98-107. [PMID: 24782263 DOI: 10.1055/s-0034-1371083] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
245 Broussier T, Lannes A, Zuberbuhler F, Oberti F, Fouchard I, Hunault G, Cales P, Boursier J. Simple blood fibrosis tests reduce unnecessary referrals for specialized evaluations of liver fibrosis in NAFLD and ALD patients. Clin Res Hepatol Gastroenterol 2020;44:349-55. [PMID: 31422033 DOI: 10.1016/j.clinre.2019.07.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
246 Nier A, Engstler AJ, Maier IB, Bergheim I. Markers of intestinal permeability are already altered in early stages of non-alcoholic fatty liver disease: Studies in children. PLoS One 2017;12:e0183282. [PMID: 28880885 DOI: 10.1371/journal.pone.0183282] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 10.3] [Reference Citation Analysis]
247 Zhan C, Kannengiesser S, Chandarana H, Fenchel M, Ream J, Shanbhogue KP. MR elastography of liver at 3 Tesla: comparison of gradient-recalled echo (GRE) and spin-echo (SE) echo-planar imaging (EPI) sequences and agreement across stiffness measurements. Abdom Radiol (NY) 2019;44:1825-33. [PMID: 30796479 DOI: 10.1007/s00261-019-01932-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
248 Younossi ZM, Stepanova M, Henry L, Racila A, Lam B, Pham HT, Hunt S. A disease-specific quality of life instrument for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: CLDQ-NAFLD. Liver Int 2017;37:1209-18. [PMID: 28211165 DOI: 10.1111/liv.13391] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 9.8] [Reference Citation Analysis]
249 Saab S, Mallam D, Cox GA 2nd, Tong MJ. Impact of coffee on liver diseases: a systematic review. Liver Int. 2014;34:495-504. [PMID: 24102757 DOI: 10.1111/liv.12304] [Cited by in Crossref: 106] [Cited by in F6Publishing: 83] [Article Influence: 13.3] [Reference Citation Analysis]
250 Yen FS, Yang YC, Hwu CM, Wei JC, Huang YH, Hou MC, Hsu CC. Liver-related long-term outcomes of thiazolidinedione use in persons with type 2 diabetes. Liver Int. 2020;40:1089-1097. [PMID: 31960563 DOI: 10.1111/liv.14385] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
251 Kim D, Kim W, Joo SK, Bae JM, Kim JH, Ahmed A. Subclinical Hypothyroidism and Low-Normal Thyroid Function Are Associated With Nonalcoholic Steatohepatitis and Fibrosis. Clin Gastroenterol Hepatol 2018;16:123-131.e1. [PMID: 28823829 DOI: 10.1016/j.cgh.2017.08.014] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 12.5] [Reference Citation Analysis]
252 Pais R, Barritt AS 4th, Calmus Y, Scatton O, Runge T, Lebray P, Poynard T, Ratziu V, Conti F. NAFLD and liver transplantation: Current burden and expected challenges. J Hepatol. 2016;65:1245-1257. [PMID: 27486010 DOI: 10.1016/j.jhep.2016.07.033] [Cited by in Crossref: 190] [Cited by in F6Publishing: 150] [Article Influence: 38.0] [Reference Citation Analysis]
253 Onofrio LI, Arocena AR, Paroli AF, Cabalén ME, Andrada MC, Cano RC, Gea S. Trypanosoma cruzi infection is a potent risk factor for non-alcoholic steatohepatitis enhancing local and systemic inflammation associated with strong oxidative stress and metabolic disorders. PLoS Negl Trop Dis 2015;9:e0003464. [PMID: 25668433 DOI: 10.1371/journal.pntd.0003464] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
254 Hart KM, Fabre T, Sciurba JC, Gieseck RL 3rd, Borthwick LA, Vannella KM, Acciani TH, de Queiroz Prado R, Thompson RW, White S, Soucy G, Bilodeau M, Ramalingam TR, Arron JR, Shoukry NH, Wynn TA. Type 2 immunity is protective in metabolic disease but exacerbates NAFLD collaboratively with TGF-β. Sci Transl Med 2017;9:eaal3694. [PMID: 28659437 DOI: 10.1126/scitranslmed.aal3694] [Cited by in Crossref: 61] [Cited by in F6Publishing: 52] [Article Influence: 20.3] [Reference Citation Analysis]
255 Sayiner M, Koenig A, Henry L, Younossi ZM. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World. Clin Liver Dis. 2016;20:205-214. [PMID: 27063264 DOI: 10.1016/j.cld.2015.10.001] [Cited by in Crossref: 247] [Cited by in F6Publishing: 208] [Article Influence: 41.2] [Reference Citation Analysis]
256 Shaked O, Demetris J, Levitsky J, Feng S, Loza BL, Punch J, Reyes J, Klintmalm G, Jackson W, DesMarais M, Sayre P, Shaked A, Reddy KR. Impact of Donor and Recipient Clinical Characteristics and Hepatic Histology on Steatosis/Fibrosis Following Liver Transplantation. Transplantation 2021. [PMID: 33982909 DOI: 10.1097/TP.0000000000003681] [Reference Citation Analysis]
257 Xu C, Ma Z, Wang Y, Liu X, Tao L, Zheng D, Guo X, Yang X. Visceral adiposity index as a predictor of NAFLD: A prospective study with 4-year follow-up. Liver Int 2018;38:2294-300. [PMID: 30099825 DOI: 10.1111/liv.13941] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
258 Siow W, van der Poorten D, George J. Epidemiological Trends in NASH as a Cause for Liver Transplant. Curr Hepatology Rep 2016;15:67-74. [DOI: 10.1007/s11901-016-0294-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.4] [Reference Citation Analysis]
259 Gemtessa TA, Chirch LM. Update on Hepatitis C Virus and HIV Coinfection. J Clin Transl Hepatol 2013;1:109-15. [PMID: 26355698 DOI: 10.14218/JCTH.2013.00018] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
260 Golabi P, Fazel S, Otgonsuren M, Sayiner M, Locklear CT, Younossi ZM. Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities. Medicine (Baltimore). 2017;96:e5904. [PMID: 28248853 DOI: 10.1097/md.0000000000005904] [Cited by in Crossref: 74] [Cited by in F6Publishing: 48] [Article Influence: 18.5] [Reference Citation Analysis]
261 Czaja AJ. Global Disparities and Their Implications in the Occurrence and Outcome of Autoimmune Hepatitis. Dig Dis Sci. 2017;62:2277-2292. [PMID: 28710658 DOI: 10.1007/s10620-017-4675-y] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 7.5] [Reference Citation Analysis]
262 Kwak HW, Park JW, Koh YH, Lee JH, Yu A, Nam BH. Clinical Characteristics of Patients with Cryptogenic Hepatocellular Carcinoma in a Hepatitis B Virus-Endemic Area. Liver Cancer 2016;5:21-36. [PMID: 26989657 DOI: 10.1159/000367756] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
263 Doycheva I, Patel N, Peterson M, Loomba R. Prognostic implication of liver histology in patients with nonalcoholic fatty liver disease in diabetes. J Diabetes Complications. 2013;27:293-300. [PMID: 23312215 DOI: 10.1016/j.jdiacomp.2012.10.008] [Cited by in Crossref: 39] [Cited by in F6Publishing: 29] [Article Influence: 4.9] [Reference Citation Analysis]
264 Wolf Greenstein A, Majumdar N, Yang P, Subbaiah PV, Kineman RD, Cordoba-Chacon J. Hepatocyte-specific, PPARγ-regulated mechanisms to promote steatosis in adult mice. J Endocrinol 2017;232:107-21. [PMID: 27799461 DOI: 10.1530/JOE-16-0447] [Cited by in Crossref: 33] [Cited by in F6Publishing: 22] [Article Influence: 6.6] [Reference Citation Analysis]
265 Puppala J, Siddapuram SP, Akka J, Munshi A. Genetics of nonalcoholic Fatty liver disease: an overview. J Genet Genomics. 2013;40:15-22. [PMID: 23357341 DOI: 10.1016/j.jgg.2012.12.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
266 Lugoboni F, Mirijello A, Morbioli L, Arzenton E, Leone R, Faccini M, Casari R, De Cosmo S, Gasbarrini A, Addolorato G. Does high-dose benzodiazepine abuse really produce liver toxicity? Results from a series of 201 benzodiazepine monoabusers. Expert Opinion on Drug Safety 2018;17:451-6. [DOI: 10.1080/14740338.2018.1457646] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
267 Schneck AS, Anty R, Patouraux S, Bonnafous S, Rousseau D, Lebeaupin C, Bailly-Maitre B, Sans A, Tran A, Gugenheim J, Iannelli A, Gual P. Roux-En Y Gastric Bypass Results in Long-Term Remission of Hepatocyte Apoptosis and Hepatic Histological Features of Non-alcoholic Steatohepatitis. Front Physiol. 2016;7:344. [PMID: 27594839 DOI: 10.3389/fphys.2016.00344] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
268 Henning JR, Graffeo CS, Rehman A, Fallon NC, Zambirinis CP, Ochi A, Barilla R, Jamal M, Deutsch M, Greco S, Ego-Osuala M, Bin-Saeed U, Rao RS, Badar S, Quesada JP, Acehan D, Miller G. Dendritic cells limit fibroinflammatory injury in nonalcoholic steatohepatitis in mice. Hepatology 2013;58:589-602. [PMID: 23322710 DOI: 10.1002/hep.26267] [Cited by in Crossref: 80] [Cited by in F6Publishing: 79] [Article Influence: 10.0] [Reference Citation Analysis]
269 Bintcliffe OJ, Arnold DT, Maskell NA. Indwelling pleural catheters for benign pleural effusions. Curr Respir Care Rep 2014;3:61-70. [DOI: 10.1007/s13665-014-0073-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
270 Fujimoto M, Tsuneyama K, Nakanishi Y, Salunga TL, Nomoto K, Sasaki Y, Iizuka S, Nagata M, Suzuki W, Shimada T, Aburada M, Shimada Y, Gershwin ME, Selmi C. A dietary restriction influences the progression but not the initiation of MSG-Induced nonalcoholic steatohepatitis. J Med Food 2014;17:374-83. [PMID: 24588719 DOI: 10.1089/jmf.2012.0029] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
271 Brouwers MCGJ, Simons N, Stehouwer CDA, Koek GH, Schaper NC, Isaacs A. Relationship Between Nonalcoholic Fatty Liver Disease Susceptibility Genes and Coronary Artery Disease. Hepatol Commun 2019;3:587-96. [PMID: 30976747 DOI: 10.1002/hep4.1319] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 9.0] [Reference Citation Analysis]
272 Zeb I, Katz R, Nasir K, Ding J, Rezaeian P, Budoff MJ. Relation of nonalcoholic fatty liver disease to the metabolic syndrome: the Multi-Ethnic Study of Atherosclerosis. J Cardiovasc Comput Tomogr 2013;7:311-8. [PMID: 24268118 DOI: 10.1016/j.jcct.2013.08.011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
273 McDonald B, Kubes P. Interactions between CD44 and Hyaluronan in Leukocyte Trafficking. Front Immunol 2015;6:68. [PMID: 25741341 DOI: 10.3389/fimmu.2015.00068] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 6.2] [Reference Citation Analysis]
274 Do A, Esserman DA, Krishnan S, Lim JK, Taddei TH, Hauser RG 3rd, Tate JP, Re VL 3rd, Justice AC. Excess Weight Gain After Cure of Hepatitis C Infection with Direct-Acting Antivirals. J Gen Intern Med 2020;35:2025-34. [PMID: 32342483 DOI: 10.1007/s11606-020-05782-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
275 Zhou Y, Lai C, Peng C, Chen M, Li B, Wang X, Sun J, Sun C. Nonalcoholic fatty liver disease as a predictor of atrial fibrillation: a systematic review and meta-analysis. Postepy Kardiol Interwencyjnej 2017;13:250-7. [PMID: 29056998 DOI: 10.5114/aic.2017.70198] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
276 Kim TW, Baek KW, Yu HS, Ko IG, Hwang L, Park JJ. High-intensity exercise improves cognitive function and hippocampal brain-derived neurotrophic factor expression in obese mice maintained on high-fat diet. J Exerc Rehabil 2020;16:124-31. [PMID: 32509696 DOI: 10.12965/jer.2040050.025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
277 Teshome G, Ambachew S, Fasil A, Abebe M. Efficacy of Glucagon-Like Peptide-1 Analogs in Nonalcoholic Fatty Liver Disease: A Systematic Review. Hepat Med 2020;12:139-51. [PMID: 33061687 DOI: 10.2147/HMER.S265631] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 7.0] [Reference Citation Analysis]
278 Meng X, Guo J, Fang W, Dou L, Li M, Huang X, Zhou S, Man Y, Tang W, Yu L, Li J. Liver MicroRNA-291b-3p Promotes Hepatic Lipogenesis through Negative Regulation of Adenosine 5'-Monophosphate (AMP)-activated Protein Kinase α1. J Biol Chem 2016;291:10625-34. [PMID: 27013659 DOI: 10.1074/jbc.M116.713768] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 4.4] [Reference Citation Analysis]
279 Mackavey CL, Hanks R. Hemostasis, coagulation abnormalities, and liver disease. Crit Care Nurs Clin North Am. 2013;25:435-46, v. [PMID: 24267280 DOI: 10.1016/j.ccell.2013.09.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
280 Lian C, Zhai Z, Li Z, Wang L. High fat diet-triggered non-alcoholic fatty liver disease: A review of proposed mechanisms. Chemico-Biological Interactions 2020;330:109199. [DOI: 10.1016/j.cbi.2020.109199] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
281 Siddiqui MS, Vuppalanchi R, Van Natta ML, Hallinan E, Kowdley KV, Abdelmalek M, Neuschwander-Tetri BA, Loomba R, Dasarathy S, Brandman D, Doo E, Tonascia JA, Kleiner DE, Chalasani N, Sanyal AJ; NASH Clinical Research Network. Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol 2019;17:156-163.e2. [PMID: 29705261 DOI: 10.1016/j.cgh.2018.04.043] [Cited by in Crossref: 112] [Cited by in F6Publishing: 83] [Article Influence: 37.3] [Reference Citation Analysis]
282 Kan H, Kimura Y, Hyogo H, Fukuhara T, Fujino H, Naeshiro N, Honda Y, Kawaoka T, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Aikata H, Ochi H, Arihiro K, Chayama K. Non-invasive assessment of liver steatosis in non-alcoholic fatty liver disease: L/S ratio of liver steatosis. Hepatol Res 2014;44:E420-7. [DOI: 10.1111/hepr.12330] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
283 Dhyani M, Anvari A, Samir AE. Ultrasound elastography: liver. Abdom Imaging 2015;40:698-708. [PMID: 25690689 DOI: 10.1007/s00261-015-0373-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
284 Liu B, Xue J, Zhang M, Wang M, Ma T, Zhao M, Gu Q, Qin S. Hydrogen inhalation alleviates nonalcoholic fatty liver disease in metabolic syndrome rats. Mol Med Rep 2020;22:2860-8. [PMID: 32945408 DOI: 10.3892/mmr.2020.11364] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
285 Yoo ER, Ahmed A, Kim D. Economic burden and healthcare utilization in nonalcoholic fatty liver disease. Hepatobiliary Surg Nutr 2019;8:181-3. [PMID: 31098375 DOI: 10.21037/hbsn.2018.12.11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
286 Anand G, Zarrinpar A, Loomba R. Targeting Dysbiosis for the Treatment of Liver Disease. Semin Liver Dis. 2016;36:37-47. [PMID: 26870931 DOI: 10.1055/s-0035-1571276] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
287 Stewart MS, Heerwagen MJ, Friedman JE. Developmental programming of pediatric nonalcoholic fatty liver disease: redefining the"first hit". Clin Obstet Gynecol 2013;56:577-90. [PMID: 23835912 DOI: 10.1097/GRF.0b013e3182a09760] [Cited by in Crossref: 29] [Cited by in F6Publishing: 11] [Article Influence: 4.1] [Reference Citation Analysis]
288 Hong Y, Dufendach K, Wang Y, Thoma F, Kilic A. Impact of hepatic steatosis on outcomes after left ventricular assist device implantation. J Card Surg 2021;36:2277-83. [PMID: 33783048 DOI: 10.1111/jocs.15536] [Reference Citation Analysis]
289 Chen T, Yan D, Cheng X, Ji X, Bian J, Yin W. miR-1224-5p Enhances Hepatic Lipogenesis by Targeting Adenosine Monophosphate–Activated Protein Kinase α1 in Male Mice. Endocrinology 2018;159:2008-21. [DOI: 10.1210/en.2017-03231] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
290 Tapper EB, Aberasturi D, Zhao Z, Hsu CY, Parikh ND. Outcomes after hepatic encephalopathy in population-based cohorts of patients with cirrhosis. Aliment Pharmacol Ther 2020;51:1397-405. [PMID: 32363684 DOI: 10.1111/apt.15749] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 11.0] [Reference Citation Analysis]
291 Jiang ZG, Tsugawa Y, Tapper EB, Lai M, Afdhal N, Robson SC, Mukamal KJ. Low-fasting triglyceride levels are associated with non-invasive markers of advanced liver fibrosis among adults in the United States. Aliment Pharmacol Ther 2015;42:106-16. [DOI: 10.1111/apt.13216] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
292 Zhu J, Cheng M, Zhao X. A tRNA-derived fragment (tRF-3001b) aggravates the development of nonalcoholic fatty liver disease by inhibiting autophagy. Life Sci 2020;257:118125. [PMID: 32702444 DOI: 10.1016/j.lfs.2020.118125] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
293 Asrani SK, Larson JJ, Yawn B, Therneau TM, Kim WR. Underestimation of liver-related mortality in the United States. Gastroenterology. 2013;145:375-382.e1-2. [PMID: 23583430 DOI: 10.1053/j.gastro.2013.04.005] [Cited by in Crossref: 172] [Cited by in F6Publishing: 146] [Article Influence: 21.5] [Reference Citation Analysis]
294 Ramadan MS, Russo V, Nigro G, Durante-Mangoni E, Zampino R. Interplay between Heart Disease and Metabolic Steatosis: A Contemporary Perspective. J Clin Med 2021;10:1569. [PMID: 33917867 DOI: 10.3390/jcm10081569] [Reference Citation Analysis]
295 Bhatt HB, Smith RJ. Fatty liver disease in diabetes mellitus. Hepatobiliary Surg Nutr. 2015;4:101-108. [PMID: 26005676 DOI: 10.3978/j.issn.2304-3881.2015.01.03] [Cited by in F6Publishing: 43] [Reference Citation Analysis]
296 Wood GC, Chu X, Argyropoulos G, Benotti P, Rolston D, Mirshahi T, Petrick A, Gabrielson J, Carey DJ, DiStefano JK, Still CD, Gerhard GS. A multi-component classifier for nonalcoholic fatty liver disease (NAFLD) based on genomic, proteomic, and phenomic data domains. Sci Rep 2017;7:43238. [PMID: 28266614 DOI: 10.1038/srep43238] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 6.5] [Reference Citation Analysis]
297 Gaspers LD, Mémin E, Thomas AP. Calcium-dependent physiologic and pathologic stimulus-metabolic response coupling in hepatocytes. Cell Calcium 2012;52:93-102. [PMID: 22564906 DOI: 10.1016/j.ceca.2012.04.009] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
298 Jaruvongvanich V, Chenbhanich J, Sanguankeo A, Rattanawong P, Wijarnpreecha K, Upala S. Increased arterial stiffness in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2017;29:e28-35. [PMID: 28542113 DOI: 10.1097/MEG.0000000000000909] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
299 Galarregui C, Marin-Alejandre BA, Perez-Diaz-Del-Campo N, Cantero I, Monreal JI, Elorz M, Benito-Boillos A, Herrero JI, Tur JA, Martínez JA, Zulet MA, Abete I. Predictive Value of Serum Ferritin in Combination with Alanine Aminotransferase and Glucose Levels for Noninvasive Assessment of NAFLD: Fatty Liver in Obesity (FLiO) Study. Diagnostics (Basel) 2020;10:E917. [PMID: 33171699 DOI: 10.3390/diagnostics10110917] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
300 Ruiz de Morales JMG, Puig L, Daudén E, Cañete JD, Pablos JL, Martín AO, Juanatey CG, Adán A, Montalbán X, Borruel N, Ortí G, Holgado-martín E, García-vidal C, Vizcaya-morales C, Martín-vázquez V, González-gay MÁ. Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies. Autoimmunity Reviews 2020;19:102429. [DOI: 10.1016/j.autrev.2019.102429] [Cited by in Crossref: 57] [Cited by in F6Publishing: 42] [Article Influence: 57.0] [Reference Citation Analysis]
301 Dong TS, Luu K, Lagishetty V, Sedighian F, Woo SL, Dreskin BW, Katzka W, Chang C, Zhou Y, Arias-Jayo N, Yang J, Ahdoot AI, Ye J, Li Z, Pisegna JR, Jacobs JP. The Intestinal Microbiome Predicts Weight Loss on a Calorie-Restricted Diet and Is Associated With Improved Hepatic Steatosis. Front Nutr 2021;8:718661. [PMID: 34307440 DOI: 10.3389/fnut.2021.718661] [Reference Citation Analysis]
302 Dasarathy S, Dasarathy J, Khiyami A, Yerian L, Hawkins C, Sargent R, McCullough AJ. Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis. J Clin Gastroenterol 2015;49:137-44. [PMID: 24583757 DOI: 10.1097/MCG.0000000000000099] [Cited by in Crossref: 99] [Cited by in F6Publishing: 44] [Article Influence: 16.5] [Reference Citation Analysis]
303 Keyes KM, Jager J, Mal-Sarkar T, Patrick ME, Rutherford C, Hasin D. Is There a Recent Epidemic of Women's Drinking? A Critical Review of National Studies. Alcohol Clin Exp Res 2019;43:1344-59. [PMID: 31074877 DOI: 10.1111/acer.14082] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 12.0] [Reference Citation Analysis]
304 Boursier J, Diehl AM. Implication of gut microbiota in nonalcoholic fatty liver disease. PLoS Pathog. 2015;11:e1004559. [PMID: 25625278 DOI: 10.1371/journal.ppat.1004559] [Cited by in Crossref: 72] [Cited by in F6Publishing: 68] [Article Influence: 12.0] [Reference Citation Analysis]
305 Oresic M. Obesity and psychotic disorders: uncovering common mechanisms through metabolomics. Dis Model Mech 2012;5:614-20. [PMID: 22915023 DOI: 10.1242/dmm.009845] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
306 Kim SS, Hwang JA, Shin HC, Choi S, Kang TW, Jou SS, Lee WH, Park S, Heo NH. LI-RADS v2017 categorisation of HCC using CT: Does moderate to severe fatty liver affect accuracy? Eur Radiol 2019;29:186-94. [DOI: 10.1007/s00330-018-5657-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
307 Cao Z, Li Z, Wang Y, Liu Y, Mo R, Ren P, Chen L, Lu J, Li H, Zhuang Y, Liu Y, Wang X, Zhao G, Tang W, Xiang X, Wang H, Cai W, Liu L, Zhu C, Bao S, Xie Q. Assessment of serum Golgi protein 73 as a biomarker for the diagnosis of significant fibrosis in patients with chronic HBV infection. J Viral Hepat. 2017;24 Suppl 1:57-65. [PMID: 29082644 DOI: 10.1111/jvh.12786] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
308 Rowe IA, Parker R, Armstrong MJ, Houlihan DD, Mutimer DJ. Hepatitis A virus vaccination in persons with hepatitis C virus infection: consequences of quality measure implementation. Hepatology 2012;56:501-6. [PMID: 22371026 DOI: 10.1002/hep.25683] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
309 Lorenzo C, Hanley AJ, Rewers MJ, Haffner SM. Discriminatory value of alanine aminotransferase for diabetes prediction: the Insulin Resistance Atherosclerosis Study. Diabet Med 2016;33:348-55. [PMID: 26094705 DOI: 10.1111/dme.12835] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
310 Elzouki AN. Probiotics and Liver Disease: Where Are We Now and Where Are We Going? J Clin Gastroenterol. 2016;50 Suppl 2, Proceedings from the 8th Probiotics, Prebiotics & amp; New Foods for Microbiota and Human Health meeting held in Rome, Italy on September 13-15, 2015:S188-S190. [PMID: 27741172 DOI: 10.1097/mcg.0000000000000712] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
311 Bayliss J, Ooi GJ, De Nardo W, Shah YJH, Montgomery MK, McLean C, Kemp W, Roberts SK, Brown WA, Burton PR, Watt MJ. Ectodysplasin A Is Increased in Non-Alcoholic Fatty Liver Disease, But Is Not Associated With Type 2 Diabetes. Front Endocrinol (Lausanne) 2021;12:642432. [PMID: 33746906 DOI: 10.3389/fendo.2021.642432] [Reference Citation Analysis]
312 Elhassan YS, Philp AA, Lavery GG. Targeting NAD+ in Metabolic Disease: New Insights Into an Old Molecule. J Endocr Soc 2017;1:816-35. [PMID: 29264533 DOI: 10.1210/js.2017-00092] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 11.3] [Reference Citation Analysis]
313 Younossi ZM, Stepanova M, Younossi Y, Golabi P, Mishra A, Rafiq N, Henry L. Epidemiology of chronic liver diseases in the USA in the past three decades. Gut 2020;69:564-8. [DOI: 10.1136/gutjnl-2019-318813] [Cited by in Crossref: 83] [Cited by in F6Publishing: 61] [Article Influence: 41.5] [Reference Citation Analysis]
314 Barbois S, Arvieux C, Leroy V, Reche F, Stürm N, Borel A. Benefit–risk of intraoperative liver biopsy during bariatric surgery: review and perspectives. Surgery for Obesity and Related Diseases 2017;13:1780-6. [DOI: 10.1016/j.soard.2017.07.032] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
315 Hagström H, Nasr P, Ekstedt M, Hammar U, Stål P, Hultcrantz R, Kechagias S. Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long-term follow-up study. Hepatol Commun 2018;2:48-57. [PMID: 29404512 DOI: 10.1002/hep4.1124] [Cited by in Crossref: 80] [Cited by in F6Publishing: 67] [Article Influence: 20.0] [Reference Citation Analysis]
316 Shenoy-Bhangle A, Baliyan V, Kordbacheh H, Guimaraes AR, Kambadakone A. Diffusion weighted magnetic resonance imaging of liver: Principles, clinical applications and recent updates. World J Hepatol. 2017;9:1081-1091. [PMID: 28989564 DOI: 10.4254/wjh.v9.i26.1081] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 5.8] [Reference Citation Analysis]
317 Vali Y, Lee J, Boursier J, Spijker R, Verheij J, Brosnan MJ, Anstee QM, Bossuyt PM, Zafarmand MH, On Behalf Of The Litmus Systematic Review Team. FibroTest for Evaluating Fibrosis in Non-Alcoholic Fatty Liver Disease Patients: A Systematic Review and Meta-Analysis. J Clin Med 2021;10:2415. [PMID: 34072480 DOI: 10.3390/jcm10112415] [Reference Citation Analysis]
318 St Pierre TG, House MJ, Bangma SJ, Pang W, Bathgate A, Gan EK, Ayonrinde OT, Bhathal PS, Clouston A, Olynyk JK, Adams LA. Stereological Analysis of Liver Biopsy Histology Sections as a Reference Standard for Validating Non-Invasive Liver Fat Fraction Measurements by MRI. PLoS One 2016;11:e0160789. [PMID: 27501242 DOI: 10.1371/journal.pone.0160789] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
319 Pfeiffer RM, Rotman Y, O'Brien TR. Genetic Determinants of Cirrhosis and Hepatocellular Carcinoma Due to Fatty Liver Disease: What's the Score? Hepatology 2020;72:794-6. [PMID: 32506469 DOI: 10.1002/hep.31413] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
320 Obmann VC, Mertineit N, Berzigotti A, Marx C, Ebner L, Kreis R, Vermathen P, Heverhagen JT, Christe A, Huber AT. CT predicts liver fibrosis: Prospective evaluation of morphology- and attenuation-based quantitative scores in routine portal venous abdominal scans. PLoS One 2018;13:e0199611. [PMID: 29990333 DOI: 10.1371/journal.pone.0199611] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.7] [Reference Citation Analysis]
321 Golabi P, Fazel S, Otgonsuren M, Escheik C, Sayiner M, Younossi ZM. Association of Parity in Patients with Chronic Liver Disease. Annals of Hepatology 2018;17:1035-41. [DOI: 10.5604/01.3001.0012.7204] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
322 Da Silva HE, Teterina A, Comelli EM, Taibi A, Arendt BM, Fischer SE, Lou W, Allard JP. Nonalcoholic fatty liver disease is associated with dysbiosis independent of body mass index and insulin resistance. Sci Rep. 2018;8:1466. [PMID: 29362454 DOI: 10.1038/s41598-018-19753-9] [Cited by in Crossref: 102] [Cited by in F6Publishing: 91] [Article Influence: 34.0] [Reference Citation Analysis]
323 Wong RJ, Chou C, Bonham CA, Concepcion W, Esquivel CO, Ahmed A. Improved survival outcomes in patients with non-alcoholic steatohepatitis and alcoholic liver disease following liver transplantation: an analysis of 2002-2012 United Network for Organ Sharing data. Clin Transplant. 2014;28:713-721. [PMID: 24654688 DOI: 10.1111/ctr.12364] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.9] [Reference Citation Analysis]
324 Liu Y, Li H, Ye N, Luo CJ, Hu YY, Wu H, Gong JP. Non-Cirrhotic Liver is Associated with Poor Prognosis of Hepatocellular Carcinoma: A Literature Review. Med Sci Monit 2019;25:6615-23. [PMID: 31479436 DOI: 10.12659/MSM.915722] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
325 Stepanova M, Younossi ZM. Economic Burden of Hepatitis C Infection. Clin Liver Dis. 2017;21:579-594. [PMID: 28689595 DOI: 10.1016/j.cld.2017.03.012] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 9.0] [Reference Citation Analysis]
326 Chang Y, Burckart GJ, Lesko LJ, Dowling TC. Evaluation of hepatic impairment dosing recommendations in FDA-approved product labels. J Clin Pharmacol 2013;53:962-6. [PMID: 23832278 DOI: 10.1002/jcph.128] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
327 Vali Y, Lee J, Boursier J, Spijker R, Löffler J, Verheij J, Brosnan MJ, Böcskei Z, Anstee QM, Bossuyt PM, Zafarmand MH, Pavlides M, Levick C, Duffin K, Hyde C, Bauer T, Bedossa P, Leeming D, Daly A, Hanf R, Ortiz P, Oresic M, Schuppan D, Hanauer G, Chen Y, Shumbayawonda E, Bjerring PN, Zwinderman K. Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis. Journal of Hepatology 2020;73:252-62. [DOI: 10.1016/j.jhep.2020.03.036] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 32.0] [Reference Citation Analysis]
328 Ni Y, Zhuge F, Nagashimada M, Nagata N, Xu L, Yamamoto S, Fuke N, Ushida Y, Suganuma H, Kaneko S, Ota T. Lycopene prevents the progression of lipotoxicity-induced nonalcoholic steatohepatitis by decreasing oxidative stress in mice. Free Radic Biol Med 2020;152:571-82. [PMID: 31790829 DOI: 10.1016/j.freeradbiomed.2019.11.036] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
329 Teschke R, Schulze J, Eickhoff A, Danan G. Drug Induced Liver Injury: Can Biomarkers Assist RUCAM in Causality Assessment? Int J Mol Sci. 2017;18:E803. [PMID: 28398242 DOI: 10.3390/ijms18040803] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 9.5] [Reference Citation Analysis]
330 Stoklosa TM, Morley KC, Volovets A, Haber PS. Pharmacotherapy for Alcohol Use Disorder in the Context of Liver Disease. Curr Addict Rep 2018;5:287-96. [DOI: 10.1007/s40429-018-0211-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
331 Han E, Cho Y, Kim KW, Lee YH, Kang ES, Cha BS, Lee BW. Hepatic fibrosis is associated with total proteinuria in Korean patients with type 2 diabetes. Medicine (Baltimore) 2020;99:e21038. [PMID: 32871978 DOI: 10.1097/MD.0000000000021038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
332 Paris T, George ES, Roberts SK, Tierney AC. The effects of diet and lifestyle interventions on insulin resistance in patients with nonalcoholic fatty liver disease: a systematic review. European Journal of Gastroenterology & Hepatology 2017;29:867-78. [DOI: 10.1097/meg.0000000000000890] [Cited by in Crossref: 5] [Article Influence: 1.3] [Reference Citation Analysis]
333 Sima A, Timar R, Vlad A, Timar B, Rosu M, Dan I, Sirli R, Popescu A, Sporea I. Nonalcoholic fatty liver disease: a frequent condition in type 2 diabetic patients. Wien Klin Wochenschr 2014;126:335-40. [PMID: 24652019 DOI: 10.1007/s00508-014-0530-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
334 Weeder PD, Porte RJ, Lisman T. Hemostasis in liver disease: implications of new concepts for perioperative management. Transfus Med Rev. 2014;28:107-113. [PMID: 24721432 DOI: 10.1016/j.tmrv.2014.03.002] [Cited by in Crossref: 83] [Cited by in F6Publishing: 63] [Article Influence: 11.9] [Reference Citation Analysis]
335 Di Ciaula A, Calamita G, Shanmugam H, Khalil M, Bonfrate L, Wang DQ, Baffy G, Portincasa P. Mitochondria Matter: Systemic Aspects of Nonalcoholic Fatty Liver Disease (NAFLD) and Diagnostic Assessment of Liver Function by Stable Isotope Dynamic Breath Tests. Int J Mol Sci 2021;22:7702. [PMID: 34299321 DOI: 10.3390/ijms22147702] [Reference Citation Analysis]
336 de Campos Mazo DF, Mattar R, Stefano JT, da Silva-Etto JM, Diniz MA, Duarte SM, Rabelo F, Lima RV, de Campos PB, Carrilho FJ, Oliveira CP. Hypolactasia is associated with insulin resistance in nonalcoholic steatohepatitis. World J Hepatol 2016;8:1019-27. [PMID: 27648154 DOI: 10.4254/wjh.v8.i24.1019] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
337 Mikolasevic I, Stojsavljevic S, Blazic F, Mijic M, Radic-Kristo D, Juric T, Skenderevic N, Klapan M, Lukic A, Filipec Kanizaj T. Noninvasive markers of liver steatosis and fibrosis after liver transplantation - Where do we stand? World J Transplant 2021;11:37-53. [PMID: 33816145 DOI: 10.5500/wjt.v11.i3.37] [Reference Citation Analysis]
338 Segovia SA, Vickers MH, Gray C, Reynolds CM. Maternal obesity, inflammation, and developmental programming. Biomed Res Int 2014;2014:418975. [PMID: 24967364 DOI: 10.1155/2014/418975] [Cited by in Crossref: 103] [Cited by in F6Publishing: 92] [Article Influence: 14.7] [Reference Citation Analysis]
339 Roeb E, Canbay A. Nichtalkoholische Fettlebererkrankungen. Gastroenterologe 2016;11:205-15. [DOI: 10.1007/s11377-016-0063-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
340 Grandison GA, Angulo P. Can NASH be diagnosed, graded, and staged noninvasively? Clin Liver Dis. 2012;16:567-585. [PMID: 22824481 DOI: 10.1016/j.cld.2012.05.001] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 4.9] [Reference Citation Analysis]
341 Pomenti S, Mehta S, Guo A, Wattacheril J. Bariatric Surgery in the Peritransplant Period. Clin Liver Dis (Hoboken) 2021;17:282-91. [PMID: 33968390 DOI: 10.1002/cld.1052] [Reference Citation Analysis]
342 Pradhan-Sundd T, Vats R, Russell JO, Singh S, Michael AA, Molina L, Kakar S, Cornuet P, Poddar M, Watkins SC, Nejak-Bowen KN, Monga SP, Sundd P. Dysregulated Bile Transporters and Impaired Tight Junctions During Chronic Liver Injury in Mice. Gastroenterology 2018;155:1218-1232.e24. [PMID: 29964040 DOI: 10.1053/j.gastro.2018.06.048] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
343 Kim D, Vazquez-Montesino LM, Escober JA, Fernandes CT, Cholankeril G, Loomba R, Harrison SA, Younossi ZM, Ahmed A. Low Thyroid Function in Nonalcoholic Fatty Liver Disease Is an Independent Predictor of All-Cause and Cardiovascular Mortality. Am J Gastroenterol 2020;115:1496-504. [PMID: 32496342 DOI: 10.14309/ajg.0000000000000654] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
344 Lee JW, Park SH. Association between depression and nonalcoholic fatty liver disease: Contributions of insulin resistance and inflammation. J Affect Disord 2021;278:259-63. [PMID: 32977263 DOI: 10.1016/j.jad.2020.09.073] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
345 Vincent R, Sanyal A. Recent Advances in Understanding of NASH: MicroRNAs as Both Biochemical Markers and Players. Curr Pathobiol Rep 2014;2:109-15. [PMID: 25574453 DOI: 10.1007/s40139-014-0049-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
346 Alt Y, Grimm A, Schlegel L, Grambihler A, Kittner JM, Wiltink J, Galle PR, Wörns MA, Schattenberg JM. The Impact of Liver Cell Injury on Health-Related Quality of Life in Patients with Chronic Liver Disease. PLoS One 2016;11:e0151200. [PMID: 26990427 DOI: 10.1371/journal.pone.0151200] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
347 Costa-Silva L, Ferolla SM, Lima AS, Vidigal PVT, Ferrari TCA. MR elastography is effective for the non-invasive evaluation of fibrosis and necroinflammatory activity in patients with nonalcoholic fatty liver disease. Eur J Radiol. 2018;98:82-89. [PMID: 29279175 DOI: 10.1016/j.ejrad.2017.11.003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
348 Deierlein AL, Rock S, Park S. Persistent Endocrine-Disrupting Chemicals and Fatty Liver Disease. Curr Environ Health Rep 2017;4:439-49. [PMID: 28980219 DOI: 10.1007/s40572-017-0166-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
349 Di Ciaula A, Passarella S, Shanmugam H, Noviello M, Bonfrate L, Wang DQ, Portincasa P. Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies? Int J Mol Sci 2021;22:5375. [PMID: 34065331 DOI: 10.3390/ijms22105375] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
350 Teschke R, Danan G. Diagnosis and Management of Drug-Induced Liver Injury (DILI) in Patients with Pre-Existing Liver Disease. Drug Saf. 2016;39:729-744. [PMID: 27091053 DOI: 10.1007/s40264-016-0423-z] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 9.3] [Reference Citation Analysis]
351 Walker RW, Belbin GM, Sorokin EP, Van Vleck T, Wojcik GL, Moscati A, Gignoux CR, Cho J, Abul-Husn NS, Nadkarni G, Kenny EE, Loos RJF. A common variant in PNPLA3 is associated with age at diagnosis of NAFLD in patients from a multi-ethnic biobank. J Hepatol 2020;72:1070-81. [PMID: 32145261 DOI: 10.1016/j.jhep.2020.01.029] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
352 Cho HJ, Hwang S, Park JI, Yang MJ, Hwang JC, Yoo BM, Lee KM, Shin SJ, Lee KJ, Kim JH, Cheong JY, Cho SW, Kim SS. Improvement of Nonalcoholic Fatty Liver Disease Reduces the Risk of Type 2 Diabetes Mellitus. Gut Liver 2019;13:440-9. [PMID: 30970431 DOI: 10.5009/gnl18382] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 17.0] [Reference Citation Analysis]
353 Khan MY, Mihali AB, Rawala MS, Aslam A, Siddiqui WJ. The promising role of probiotic and synbiotic therapy in aminotransferase levels and inflammatory markers in patients with nonalcoholic fatty liver disease - a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2019;31:703-15. [PMID: 31009401 DOI: 10.1097/MEG.0000000000001371] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
354 Younossi ZM, Stepanova M, Ong J, Yilmaz Y, Duseja A, Eguchi Y, El Kassas M, Castellanos-fernandez M, George J, Jacobson IM, Bugianesi E, Wong VW, Arrese M, de Ledinghen V, Romero-gomez M, Mendez-sanchez N, Ahmed A, Wong R, Papatheodoridis G, Serfaty L, Younossi I, Nader F, Ziayee M, Afendy A. Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease. Clinical Gastroenterology and Hepatology 2019;17:1625-1633.e1. [DOI: 10.1016/j.cgh.2018.11.033] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 22.0] [Reference Citation Analysis]
355 Musso G, Cassader M, Gambino R. Cholesterol-lowering therapy for the treatment of nonalcoholic fatty liver disease: an update. Curr Opin Lipidol 2011;22:489-96. [PMID: 21986643 DOI: 10.1097/MOL.0b013e32834c37ee] [Cited by in Crossref: 34] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
356 Satkunasingham J, Besa C, Bane O, Shah A, de Oliveira A, Gilson WD, Kannengiesser S, Taouli B. Liver fat quantification: Comparison of dual-echo and triple-echo chemical shift MRI to MR spectroscopy. Eur J Radiol. 2015;84:1452-1458. [PMID: 26047820 DOI: 10.1016/j.ejrad.2015.05.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
357 Basu PP, Aloysius MM, Shah NJ, Brown RS. Review article: the endocannabinoid system in liver disease, a potential therapeutic target. Aliment Pharmacol Ther. 2014;39:790-801. [PMID: 24612021 DOI: 10.1111/apt.12673] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
358 Schneier AT, Citti CC, Dieterich DT. Management and diagnosis of fatty liver disease. Expert Rev Gastroenterol Hepatol. 2015;9:671-683. [PMID: 25716275 DOI: 10.1586/17474124.2015.1003209] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
359 Moura Cunha G, Navin PJ, Fowler KJ, Venkatesh SK, Ehman RL, Sirlin CB. Quantitative magnetic resonance imaging for chronic liver disease. Br J Radiol 2021;94:20201377. [PMID: 33635729 DOI: 10.1259/bjr.20201377] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
360 Akhtar DH, Iqbal U, Vazquez-Montesino LM, Dennis BB, Ahmed A. Pathogenesis of Insulin Resistance and Atherogenic Dyslipidemia in Nonalcoholic Fatty Liver Disease. J Clin Transl Hepatol. 2019;7:362-370. [PMID: 31915606 DOI: 10.14218/jcth.2019.00028] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
361 Yilmaz Y, Younossi ZM. Obesity-associated nonalcoholic fatty liver disease. Clin Liver Dis. 2014;18:19-31. [PMID: 24274862 DOI: 10.1016/j.cld.2013.09.018] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 5.9] [Reference Citation Analysis]
362 Mullin GE. The Use of Complementary and Alternative Medicine for Liver Disease: Part I. Nutr Clin Pract 2013;28:138-9. [DOI: 10.1177/0884533612471766] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
363 Setiawan VW, Stram DO, Porcel J, Lu SC, Le Marchand L, Noureddin M. Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: The multiethnic cohort. Hepatology. 2016;64:1969-1977. [PMID: 27301913 DOI: 10.1002/hep.28677] [Cited by in Crossref: 147] [Cited by in F6Publishing: 110] [Article Influence: 29.4] [Reference Citation Analysis]
364 Perumpail BJ, Khan MA, Yoo ER, Cholankeril G, Kim D, Ahmed A. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol. 2017;23:8263-8276. [PMID: 29307986 DOI: 10.3748/wjg.v23.i47.8263] [Cited by in CrossRef: 234] [Cited by in F6Publishing: 191] [Article Influence: 78.0] [Reference Citation Analysis]
365 Noureddin M, Mato JM, Lu SC. Nonalcoholic fatty liver disease: update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine. Exp Biol Med (Maywood). 2015;240:809-820. [PMID: 25873078 DOI: 10.1177/1535370215579161] [Cited by in Crossref: 57] [Cited by in F6Publishing: 42] [Article Influence: 9.5] [Reference Citation Analysis]
366 Tapper EB, Henderson JB, Parikh ND, Ioannou GN, Lok AS. Incidence of and Risk Factors for Hepatic Encephalopathy in a Population-Based Cohort of Americans With Cirrhosis. Hepatol Commun 2019;3:1510-9. [PMID: 31701074 DOI: 10.1002/hep4.1425] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 9.0] [Reference Citation Analysis]
367 Flanagan S, Minassian SL, Morris D, Ponnuraj R, Marbury TC, Alcorn HW, Fang E, Prokocimer P. Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment. Antimicrob Agents Chemother 2014;58:6471-6. [PMID: 25136024 DOI: 10.1128/AAC.03431-14] [Cited by in Crossref: 41] [Cited by in F6Publishing: 15] [Article Influence: 5.9] [Reference Citation Analysis]
368 Raselli T, Hearn T, Wyss A, Atrott K, Peter A, Frey-Wagner I, Spalinger MR, Maggio EM, Sailer AW, Schmitt J, Schreiner P, Moncsek A, Mertens J, Scharl M, Griffiths WJ, Bueter M, Geier A, Rogler G, Wang Y, Misselwitz B. Elevated oxysterol levels in human and mouse livers reflect nonalcoholic steatohepatitis. J Lipid Res 2019;60:1270-83. [PMID: 31113816 DOI: 10.1194/jlr.M093229] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
369 Lonardo A, Leoni S, Alswat KA, Fouad Y. History of Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2020;21:E5888. [PMID: 32824337 DOI: 10.3390/ijms21165888] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 18.0] [Reference Citation Analysis]
370 Wijarnpreecha K, Thongprayoon C, Edmonds P, Cheungpasitporn W. Associations of sugar- and artificially sweetened soda with nonalcoholic fatty liver disease: a systematic review and meta-analysis. QJM 2016;109:461-6. [DOI: 10.1093/qjmed/hcv172] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 4.8] [Reference Citation Analysis]
371 Stepanova M, Wai H, Saab S, Mishra A, Venkatesan C, Younossi ZM. The outcomes of adult liver transplants in the United States from 1987 to 2013. Liver Int 2015;35:2036-41. [PMID: 25559873 DOI: 10.1111/liv.12779] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
372 Shamseddeen H, Pike F, Ghabril M, Patidar KR, Desai AP, Nephew L, Anderson M, Kubal C, Chalasani N, Orman ES. Karnofsky performance status predicts outcomes in candidates for simultaneous liver-kidney transplant. Clin Transplant 2021;35:e14190. [PMID: 33320383 DOI: 10.1111/ctr.14190] [Reference Citation Analysis]
373 Flemming JA, Dewit Y, Mah JM, Saperia J, Groome PA, Booth CM. Incidence of cirrhosis in young birth cohorts in Canada from 1997 to 2016: a retrospective population-based study. Lancet Gastroenterol Hepatol 2019;4:217-26. [PMID: 30573390 DOI: 10.1016/S2468-1253(18)30339-X] [Cited by in Crossref: 28] [Cited by in F6Publishing: 13] [Article Influence: 9.3] [Reference Citation Analysis]
374 Jun TW, Yeh ML, Yang JD, Chen VL, Nguyen P, Giama NH, Huang CF, Hsing AW, Dai CY, Huang JF, Chuang WL, Roberts LR, Yu ML, Nguyen MH. More advanced disease and worse survival in cryptogenic compared to viral hepatocellular carcinoma. Liver Int 2018;38:895-902. [PMID: 29045023 DOI: 10.1111/liv.13613] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
375 Sterling RK, Sanyal AJ. Pentoxifylline for steatohepatitis: magic bullet or smoking gun? Hepatology 2011;54:1496-9. [PMID: 22045667 DOI: 10.1002/hep.24612] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
376 Elmeliegy M, Yang DZ, Salama E, Parivar K, Wang DD. Discordance Between Child-Pugh and National Cancer Institute Classifications for Hepatic Dysfunction: Implications on Dosing Recommendations for Oncology Compounds. J Clin Pharmacol 2021;61:105-15. [PMID: 32691438 DOI: 10.1002/jcph.1702] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
377 Moore A, Wu L, Chuang JC, Sun X, Luo X, Gopal P, Li L, Celen C, Zimmer M, Zhu H. Arid1a Loss Drives Nonalcoholic Steatohepatitis in Mice Through Epigenetic Dysregulation of Hepatic Lipogenesis and Fatty Acid Oxidation. Hepatology 2019;69:1931-45. [PMID: 30584660 DOI: 10.1002/hep.30487] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
378 Mir IH, Guha S, Behera J, Thirunavukkarasu C. Targeting molecular signal transduction pathways in hepatocellular carcinoma and its implications for cancer therapy. Cell Biol Int 2021. [PMID: 34270844 DOI: 10.1002/cbin.11670] [Reference Citation Analysis]
379 Dasarathy J, Varghese R, Feldman A, Khiyami A, McCullough AJ, Dasarathy S. Patients with Nonalcoholic Fatty Liver Disease Have a Low Response Rate to Vitamin D Supplementation. J Nutr 2017;147:1938-46. [PMID: 28814531 DOI: 10.3945/jn.117.254292] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
380 Rong Y, Chun-yan N, Hong-xin Z, Lu Y, Wen W, Yu T. Association of Adolescent Obesity with Nonalcoholic Fatty Liver Disease and Related Risk Factors in Xi ’an, China. Annals of Hepatology 2018;17:85-91. [DOI: 10.5604/01.3001.0010.7538] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
381 Abul-Husn NS, Cheng X, Li AH, Xin Y, Schurmann C, Stevis P, Liu Y, Kozlitina J, Stender S, Wood GC, Stepanchick AN, Still MD, McCarthy S, O'Dushlaine C, Packer JS, Balasubramanian S, Gosalia N, Esopi D, Kim SY, Mukherjee S, Lopez AE, Fuller ED, Penn J, Chu X, Luo JZ, Mirshahi UL, Carey DJ, Still CD, Feldman MD, Small A, Damrauer SM, Rader DJ, Zambrowicz B, Olson W, Murphy AJ, Borecki IB, Shuldiner AR, Reid JG, Overton JD, Yancopoulos GD, Hobbs HH, Cohen JC, Gottesman O, Teslovich TM, Baras A, Mirshahi T, Gromada J, Dewey FE. A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease. N Engl J Med. 2018;378:1096-1106. [PMID: 29562163 DOI: 10.1056/nejmoa1712191] [Cited by in Crossref: 274] [Cited by in F6Publishing: 126] [Article Influence: 91.3] [Reference Citation Analysis]
382 Lau E, Carvalho D, Freitas P. Gut Microbiota: Association with NAFLD and Metabolic Disturbances. Biomed Res Int. 2015;2015:979515. [PMID: 26090468 DOI: 10.1155/2015/979515] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 5.7] [Reference Citation Analysis]
383 Diedrich T, Kummer S, Galante A, Drolz A, Schlicker V, Lohse AW, Kluwe J, Eberhard JM, Schulze Zur Wiesch J. Characterization of the immune cell landscape of patients with NAFLD. PLoS One 2020;15:e0230307. [PMID: 32168345 DOI: 10.1371/journal.pone.0230307] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
384 Blakely AM, Manning KL, Tripathi A, Morgan JR. Bio-Pick, Place, and Perfuse: A New Instrument for Three-Dimensional Tissue Engineering. Tissue Eng Part C Methods 2015;21:737-46. [PMID: 25530515 DOI: 10.1089/ten.TEC.2014.0439] [Cited by in Crossref: 42] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
385 Scaglioni F, Marino M, Ciccia S, Procaccini A, Busacchi M, Loria P, Lonardo A, Malavolti M, Battistini NC, Pellegrini M, Carubbi F, Bellentani S. Short-term multidisciplinary non-pharmacological intervention is effective in reducing liver fat content assessed non-invasively in patients with nonalcoholic fatty liver disease (NAFLD). Clinics and Research in Hepatology and Gastroenterology 2013;37:353-8. [DOI: 10.1016/j.clinre.2012.10.009] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
386 Wijarnpreecha K, Thongprayoon C, Scribani M, Ungprasert P, Cheungpasitporn W. Noninvasive fibrosis markers and chronic kidney disease among adults with nonalcoholic fatty liver in USA. Eur J Gastroenterol Hepatol. 2018;30:404-410. [PMID: 29215435 DOI: 10.1097/meg.0000000000001045] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
387 Younossi Z, Henry L. Contribution of Alcoholic and Nonalcoholic Fatty Liver Disease to the Burden of Liver-Related Morbidity and Mortality. Gastroenterology. 2016;150:1778-1785. [PMID: 26980624 DOI: 10.1053/j.gastro.2016.03.005] [Cited by in Crossref: 141] [Cited by in F6Publishing: 114] [Article Influence: 28.2] [Reference Citation Analysis]
388 Salameh H, Masadeh M, Al Hanayneh M, Petros V, Maslonka M, Nanda A, Singal AK. PNPLA3 polymorphism increases risk for and severity of chronic hepatitis C liver disease. World J Hepatol 2016;8:1584-92. [PMID: 28050240 DOI: 10.4254/wjh.v8.i35.1584] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
389 Motamed N, Nikkhah M, Karbalaie Niya MH, Khoonsari M, Perumal D, Ashrafi GH, Faraji AH, Maadi M, Ajdarkosh H, Safarnezhad Tameshkel F, Moradi-Lakeh M, Miri SM, Arsang-Jang S, Zamani F. The Ability of the Framingham Steatosis Index (FSI) to Predict Non-alcoholic Fatty Liver Disease (NAFLD): A Cohort Study. Clin Res Hepatol Gastroenterol 2021;45:101567. [PMID: 33711631 DOI: 10.1016/j.clinre.2020.10.011] [Reference Citation Analysis]
390 Veiga-Lopez A, Pu Y, Gingrich J, Padmanabhan V. Obesogenic Endocrine Disrupting Chemicals: Identifying Knowledge Gaps. Trends Endocrinol Metab 2018;29:607-25. [PMID: 30017741 DOI: 10.1016/j.tem.2018.06.003] [Cited by in Crossref: 42] [Cited by in F6Publishing: 33] [Article Influence: 14.0] [Reference Citation Analysis]
391 Ghaemi A, Hosseini N, Osati S, Naghizadeh MM, Dehghan A, Ehrampoush E, Honarvar B, Homayounfar R. Waist circumference is a mediator of dietary pattern in Non-alcoholic fatty liver disease. Sci Rep. 2018;8:4788. [PMID: 29555959 DOI: 10.1038/s41598-018-23192-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
392 Mariqueo TA, Zúñiga-Hernández J. Omega-3 derivatives, specialized pro-resolving mediators: Promising therapeutic tools for the treatment of pain in chronic liver disease. Prostaglandins Leukot Essent Fatty Acids 2020;158:102095. [PMID: 32450460 DOI: 10.1016/j.plefa.2020.102095] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
393 Gou XJ, Gao S, Chen L, Feng Q, Hu YY. A Metabolomic Study on the Intervention of Traditional Chinese Medicine Qushi Huayu Decoction on Rat Model of Fatty Liver Induced by High-Fat Diet. Biomed Res Int 2019;2019:5920485. [PMID: 30881991 DOI: 10.1155/2019/5920485] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
394 Wan F, Pan F, Ayonrinde OT, Adams LA, Mori TA, Beilin LJ, O'Sullivan TA, Olynyk JK, Oddy WH. Validation of fatty liver disease scoring systems for ultrasound diagnosed non-alcoholic fatty liver disease in adolescents. Dig Liver Dis 2021;53:746-52. [PMID: 33334704 DOI: 10.1016/j.dld.2020.11.037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
395 Jiao J, Kwan SY, Sabotta CM, Tanaka H, Veillon L, Warmoes MO, Lorenzi PL, Wang Y, Wei P, Hawk ET, Almeda JL, McCormick JB, Fisher-Hoch SP, Beretta L. Circulating Fatty Acids Associated with Advanced Liver Fibrosis and Hepatocellular Carcinoma in South Texas Hispanics. Cancer Epidemiol Biomarkers Prev 2021;30:1643-51. [PMID: 34155064 DOI: 10.1158/1055-9965.EPI-21-0183] [Reference Citation Analysis]
396 Koeckerling D, Tomlinson JW, Cobbold JF. Fighting liver fat. Endocr Connect 2020;9:R173-86. [PMID: 32621584 DOI: 10.1530/EC-20-0174] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
397 DiNicolantonio JJ, Subramonian AM, O'Keefe JH. Added fructose as a principal driver of non-alcoholic fatty liver disease: a public health crisis. Open Heart 2017;4:e000631. [PMID: 29118995 DOI: 10.1136/openhrt-2017-000631] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
398 Filozof C, Chow SC, Dimick-Santos L, Chen YF, Williams RN, Goldstein BJ, Sanyal A. Clinical endpoints and adaptive clinical trials in precirrhotic nonalcoholic steatohepatitis: Facilitating development approaches for an emerging epidemic. Hepatol Commun 2017;1:577-85. [PMID: 29404480 DOI: 10.1002/hep4.1079] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 6.5] [Reference Citation Analysis]
399 Shin A, Xu H, Imperiale TF. Associations of chronic diarrhoea with non-alcoholic fatty liver disease and obesity-related disorders among US adults. BMJ Open Gastroenterol 2019;6:e000322. [PMID: 31523443 DOI: 10.1136/bmjgast-2019-000322] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
400 Zamani N, Shams M, Nimrouzi M, Zarshenas MM, Abolhasani Foroughi A, Fallahzadeh Abarghooei E, Fattahi MR. The effects of Zataria multiflora Boiss. (Shirazi thyme) on nonalcoholic fatty liver disease and insulin resistance: A randomized double-blind placebo-controlled clinical trial. Complement Ther Med 2018;41:118-23. [PMID: 30477827 DOI: 10.1016/j.ctim.2018.09.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
401 Tapper EB, Parikh ND. Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study. BMJ 2018;362:k2817. [PMID: 30021785 DOI: 10.1136/bmj.k2817] [Cited by in Crossref: 248] [Cited by in F6Publishing: 218] [Article Influence: 82.7] [Reference Citation Analysis]
402 Smith RJ. Nutrition and metabolism in hepatocellular carcinoma. Hepatobiliary Surg Nutr 2013;2:89-96. [PMID: 24570922 DOI: 10.3978/j.issn.2304-3881.2012.11.02] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
403 Long MT, Ko D, Arnold LM, Trinquart L, Sherer JA, Keppel SS, Benjamin EJ, Helm RH. Gastrointestinal and liver diseases and atrial fibrillation: a review of the literature. Therap Adv Gastroenterol 2019;12:1756284819832237. [PMID: 30984290 DOI: 10.1177/1756284819832237] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
404 Bouziana SD, Tziomalos K. Inhibition of apoptosis in the management of nonalcoholic fatty liver disease. World J Gastrointest Pharmacol Ther. 2013;4:4-8. [PMID: 23516172 DOI: 10.4292/wjgpt.v4.i1.4] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
405 Hernandez Roman J, Siddiqui MS. The role of noninvasive biomarkers in diagnosis and risk stratification in nonalcoholic fatty liver disease. Endocrinol Diabetes Metab 2020;3:e00127. [PMID: 33102796 DOI: 10.1002/edm2.127] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
406 Chen LW, Chien CH, Kuo SF, Yu CY, Lin CL, Chien RN. Low vitamin D level was associated with metabolic syndrome and high leptin level in subjects with nonalcoholic fatty liver disease: a community-based study. BMC Gastroenterol 2019;19:126. [PMID: 31311491 DOI: 10.1186/s12876-019-1040-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
407 Gitto S, Vukotic R, Vitale G, Pirillo M, Villa E, Andreone P. Non-alcoholic steatohepatitis and liver transplantation. Dig Liver Dis. 2016;48:587-591. [PMID: 27038703 DOI: 10.1016/j.dld.2016.02.014] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
408 Venkatesh SK, Hennedige T, Johnson GB, Hough DM, Fletcher JG. Imaging patterns and focal lesions in fatty liver: a pictorial review. Abdom Radiol (NY) 2017;42:1374-92. [PMID: 27999887 DOI: 10.1007/s00261-016-1002-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
409 Anand A, Elhence A, Vaishnav M, Singh AA, Rajput MS, Banyal V, Jindal V, Pathak P, Kumar P, Nayak B, Yadav R, Das P, Garg H, Agarwal L, Aggarwal S, Kumar R, Shalimar. FibroScan-aspartate aminotransferase score in an Asian cohort of non-alcoholic fatty liver disease and its utility in predicting histological resolution with bariatric surgery. J Gastroenterol Hepatol 2021;36:1309-16. [PMID: 33232525 DOI: 10.1111/jgh.15358] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
410 Bellentani S. The epidemiology of non-alcoholic fatty liver disease. Liver Int. 2017;37 Suppl 1:81-84. [PMID: 28052624 DOI: 10.1111/liv.13299] [Cited by in Crossref: 312] [Cited by in F6Publishing: 244] [Article Influence: 78.0] [Reference Citation Analysis]
411 Mendes LC, Ferreira PA, Miotto N, Zanaga L, Lazarini MS, Gonçales ESL, Pedro MN, Gonçales FL Júnior, Stucchi RSB, Vigani AG. Controlled attenuation parameter for steatosis grading in chronic hepatitis C compared with digital morphometric analysis of liver biopsy: impact of individual elastography measurement quality. Eur J Gastroenterol Hepatol 2018;30:959-66. [PMID: 29727388 DOI: 10.1097/MEG.0000000000001145] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
412 Sherif ZA, Saeed A, Ghavimi S, Nouraie SM, Laiyemo AO, Brim H, Ashktorab H. Global Epidemiology of Nonalcoholic Fatty Liver Disease and Perspectives on US Minority Populations. Dig Dis Sci. 2016;61:1214-1225. [PMID: 27038448 DOI: 10.1007/s10620-016-4143-0] [Cited by in Crossref: 83] [Cited by in F6Publishing: 68] [Article Influence: 16.6] [Reference Citation Analysis]
413 Tanoglu A, Kara M. Nonalcoholic fatty liver disease-related cardiovascular risk: Is there an association with blood hemoglobin levels? Eur J Gastroenterol Hepatol. 2015;27:1126-1129. [PMID: 26193051 DOI: 10.1097/meg.0000000000000434] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 1.6] [Reference Citation Analysis]
414 Stephenson K, Kennedy L, Hargrove L, Demieville J, Thomson J, Alpini G, Francis H. Updates on Dietary Models of Nonalcoholic Fatty Liver Disease: Current Studies and Insights. Gene Expr. 2018;18:5-17. [PMID: 29096730 DOI: 10.3727/105221617x15093707969658] [Cited by in Crossref: 40] [Cited by in F6Publishing: 24] [Article Influence: 10.0] [Reference Citation Analysis]
415 Poynard T, Munteanu M, Deckmyn O, Ngo Y, Drane F, Castille JM, Housset C, Ratziu V, Imbert-Bismut F. Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population. J Hepatol. 2012;57:541-548. [PMID: 22612998 DOI: 10.1016/j.jhep.2012.04.025] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 5.3] [Reference Citation Analysis]
416 Park H, Hwang YH, Kim DG, Jeon J, Ma JY. Hepatoprotective effect of herb formula KIOM2012H against nonalcoholic fatty liver disease. Nutrients 2015;7:2440-55. [PMID: 25849950 DOI: 10.3390/nu7042440] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
417 Imajo K, Yoneda M, Ogawa Y, Wada K, Nakajima A. Microbiota and nonalcoholic steatohepatitis. Semin Immunopathol. 2014;36:115-132. [PMID: 24337650 DOI: 10.1007/s00281-013-0404-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
418 Takyar V, Nath A, Beri A, Gharib AM, Rotman Y. How healthy are the "Healthy volunteers"? Penetrance of NAFLD in the biomedical research volunteer pool. Hepatology 2017;66:825-33. [PMID: 28470683 DOI: 10.1002/hep.29247] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 4.8] [Reference Citation Analysis]
419 Lim U, Monroe KR, Buchthal S, Fan B, Cheng I, Kristal BS, Lampe JW, Hullar MA, Franke AA, Stram DO, Wilkens LR, Shepherd J, Ernst T, Le Marchand L. Propensity for Intra-abdominal and Hepatic Adiposity Varies Among Ethnic Groups. Gastroenterology 2019;156:966-975.e10. [PMID: 30445012 DOI: 10.1053/j.gastro.2018.11.021] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 11.0] [Reference Citation Analysis]
420 Tokodai K, Karadagi A, Kjaernet F, Romano A, Ericzon BG, Nowak G. Characteristics and risk factors for recurrence of nonalcoholic steatohepatitis following liver transplantation. Scand J Gastroenterol 2019;54:233-9. [PMID: 30999770 DOI: 10.1080/00365521.2019.1577484] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
421 Golabi P, Sayiner M, Fazel Y, Koenig A, Henry L, Younossi ZM. Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis. Expert Rev Gastroenterol Hepatol. 2016;10:63-71. [PMID: 26469309 DOI: 10.1586/17474124.2016.1099433] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 5.7] [Reference Citation Analysis]
422 Mohammadifard M, Saremi Z, Rastgoo M, Akbari E. Relevance between Helicobacter pylori Infection and Non-Alcoholic Fatty Liver Disease in Birjand, Iran. J Med Life 2019;12:168-72. [PMID: 31406519 DOI: 10.25122/jml-2019-0012] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
423 Seo NK, Koo HS, Haam JH, Kim HY, Kim MJ, Park KC, Park KS, Kim YS. Prediction of prevalent but not incident non-alcoholic fatty liver disease by levels of serum testosterone. J Gastroenterol Hepatol 2015;30:1211-6. [PMID: 25708291 DOI: 10.1111/jgh.12935] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
424 Sevastianova K, Dean J, Bannan C, Coghlan M, Farrell G, Murray C, De Gascun CF, Bergin C. NS5A resistance leading to failure of 24-week therapy with sofosbuvir/ledipasvir and ribavirin for the treatment of hepatitis C genotype 1a infection in a HIV-1 co-infected patient. J Clin Virol 2016;82:66-9. [PMID: 27454231 DOI: 10.1016/j.jcv.2016.06.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
425 Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, Ahmed A. Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States. Gastroenterology 2015;148:547-55. [DOI: 10.1053/j.gastro.2014.11.039] [Cited by in Crossref: 970] [Cited by in F6Publishing: 811] [Article Influence: 161.7] [Reference Citation Analysis]
426 Dhyani M, Xiang F, Li Q, Chen L, Li C, Bhan AK, Anthony B, Grajo JR, Samir AE. Ultrasound Shear Wave Elastography: Variations of Liver Fibrosis Assessment as a Function of Depth, Force and Distance from Central Axis of the Transducer with a Comparison of Different Systems. Ultrasound Med Biol 2018;44:2209-22. [PMID: 30143339 DOI: 10.1016/j.ultrasmedbio.2018.07.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
427 Zhang S, Li Y, Wang G, Tan R, Tsoi B, Mao G, Zhai Y, Cao L, Chen M, Kurihara H, Wang Q, He R. Caffeine ameliorates high energy diet-induced hepatic steatosis: sirtuin 3 acts as a bridge in the lipid metabolism pathway. Food Funct 2015;6:2578-87. [DOI: 10.1039/c5fo00247h] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
428 Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, Gelfand JM. Psoriasis and comorbid diseases: Epidemiology. J Am Acad Dermatol 2017;76:377-90. [PMID: 28212759 DOI: 10.1016/j.jaad.2016.07.064] [Cited by in Crossref: 296] [Cited by in F6Publishing: 220] [Article Influence: 74.0] [Reference Citation Analysis]
429 Sulava E, Bergin S, Long B, Koyfman A. Elevated Liver Enzymes: Emergency Department-Focused Management. J Emerg Med 2017;52:654-67. [PMID: 27889359 DOI: 10.1016/j.jemermed.2016.10.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
430 Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-jack S, Davidson MB, Einhorn D, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, Mcgill JB, Mechanick JI, Rosenblit PD, Umpierrez GE, Davidson MH. American Association of Clinical Endocrinologists’ Comprehensive Diabetes Management Algorithm 2013 Consensus Statement. Endocrine Practice 2013;19:1-48. [DOI: 10.4158/ep13176.csuppl] [Cited by in Crossref: 81] [Article Influence: 10.1] [Reference Citation Analysis]
431 Venkatesh SK, Ehman RL. Magnetic resonance elastography of abdomen. Abdom Imaging. 2015;40:745-759. [PMID: 25488346 DOI: 10.1007/s00261-014-0315-6] [Cited by in Crossref: 54] [Cited by in F6Publishing: 40] [Article Influence: 9.0] [Reference Citation Analysis]
432 Ho SB, Matheny ME, Schnabl BE. Changes in Hospital Admissions and Mortality for Complications of Cirrhosis: Implications for Clinicians and Health Systems. Gut Liver 2016;10:8-9. [PMID: 26696026 DOI: 10.5009/gnl15593] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
433 Kälsch J, Bechmann LP, Heider D, Best J, Manka P, Kälsch H, Sowa JP, Moebus S, Slomiany U, Jöckel KH, Erbel R, Gerken G, Canbay A. Normal liver enzymes are correlated with severity of metabolic syndrome in a large population based cohort. Sci Rep 2015;5:13058. [PMID: 26269425 DOI: 10.1038/srep13058] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 6.5] [Reference Citation Analysis]
434 Imajo K, Fujita K, Yoneda M, Nozaki Y, Ogawa Y, Shinohara Y, Kato S, Mawatari H, Shibata W, Kitani H, Ikejima K, Kirikoshi H, Nakajima N, Saito S, Maeyama S, Watanabe S, Wada K, Nakajima A. Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin-mediated signaling. Cell Metab 2012;16:44-54. [PMID: 22768838 DOI: 10.1016/j.cmet.2012.05.012] [Cited by in Crossref: 194] [Cited by in F6Publishing: 177] [Article Influence: 21.6] [Reference Citation Analysis]
435 Rosso C, Mezzabotta L, Gaggini M, Salomone F, Gambino R, Marengo A, Saba F, Vanni E, Jouness RI, Saponaro C. Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease. Hepatology. 2016;63:107-116. [PMID: 26473614 DOI: 10.1002/hep.28287] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 6.0] [Reference Citation Analysis]
436 Muriel P. The Liver. Liver Pathophysiology. Elsevier; 2017. pp. 3-22. [DOI: 10.1016/b978-0-12-804274-8.00001-1] [Cited by in Crossref: 10] [Article Influence: 2.5] [Reference Citation Analysis]
437 Reddy SK, Steel JL, Chen H, Demateo DJ, Cardinal J, Behari J, Humar A, Marsh JW, Geller DA, Tsung A. Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease. Hepatology 2012;55:1809-19. [DOI: 10.1002/hep.25536] [Cited by in Crossref: 124] [Cited by in F6Publishing: 109] [Article Influence: 13.8] [Reference Citation Analysis]
438 Loria A, Escheik C, Gerber NL, Younossi ZM. Quality of life in cirrhosis. Curr Gastroenterol Rep 2013;15:301. [PMID: 23250701 DOI: 10.1007/s11894-012-0301-5] [Cited by in Crossref: 48] [Cited by in F6Publishing: 38] [Article Influence: 6.0] [Reference Citation Analysis]
439 Grattagliano I, Di Ciaula A, Baj J, Molina-Molina E, Shanmugam H, Garruti G, Wang DQ, Portincasa P. Protocols for Mitochondria as the Target of Pharmacological Therapy in the Context of Nonalcoholic Fatty Liver Disease (NAFLD). Methods Mol Biol 2021;2310:201-46. [PMID: 34096005 DOI: 10.1007/978-1-0716-1433-4_12] [Reference Citation Analysis]
440 Demir M, Lang S, Steffen HM. Nonalcoholic fatty liver disease - current status and future directions. J Dig Dis 2015;16:541-57. [PMID: 26406351 DOI: 10.1111/1751-2980.12291] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 11.6] [Reference Citation Analysis]
441 Hayat U, Siddiqui AA, Okut H, Afroz S, Tasleem S, Haris A. The effect of coffee consumption on the non-alcoholic fatty liver disease and liver fibrosis: A meta-analysis of 11 epidemiological studies. Ann Hepatol 2021;20:100254. [PMID: 32920163 DOI: 10.1016/j.aohep.2020.08.071] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
442 Wirth KM, Sheka AC, Kizy S, Irey R, Benner A, Sieger G, Simon G, Ma S, Lake J, Aliferis C, Leslie D, Marmor S, Ikramuddin S. Bariatric Surgery is Associated With Decreased Progression of Nonalcoholic Fatty Liver Disease to Cirrhosis: A Retrospective Cohort Analysis. Ann Surg 2020;272:32-9. [PMID: 32224733 DOI: 10.1097/SLA.0000000000003871] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 14.0] [Reference Citation Analysis]
443 Lee J, Vali Y, Boursier J, Duffin K, Verheij J, Brosnan MJ, Zwinderman K, Anstee QM, Bossuyt PM, Zafarmand MH. Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: A systematic review and meta-analysis. PLoS One 2020;15:e0238717. [PMID: 32915852 DOI: 10.1371/journal.pone.0238717] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
444 Ferolla SM, Armiliato GN, Couto CA, Ferrari TC. Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease. World J Hepatol. 2015;7:559-565. [PMID: 25848479 DOI: 10.4254/wjh.v7.i3.559] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
445 Huang SC, Su HJ, Kao JH, Tseng TC, Yang HC, Su TH, Chen PJ, Liu CJ. Clinical and Histologic Features of Patients with Biopsy-Proven Metabolic Dysfunction-Associated Fatty Liver Disease. Gut Liver 2021;15:451-8. [PMID: 33431715 DOI: 10.5009/gnl20218] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
446 Patel R, Baker SS, Liu W, Desai S, Alkhouri R, Kozielski R, Mastrandrea L, Sarfraz A, Cai W, Vlassara H. Effect of dietary advanced glycation end products on mouse liver. PLoS One. 2012;7:e35143. [PMID: 22496902 DOI: 10.1371/journal.pone.0035143] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 5.9] [Reference Citation Analysis]
447 Ip BC, Wang XD. Non-alcoholic steatohepatitis and hepatocellular carcinoma: implications for lycopene intervention. Nutrients. 2014;6:124-162. [PMID: 24379011 DOI: 10.3390/nu6010124] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
448 Aoki S, Iwai A, Kawata K, Muramatsu D, Uchiyama H, Okabe M, Ikesue M, Maeda N, Uede T. Oral administration of the Aureobasidium pullulans-derived β-glucan effectively prevents the development of high fat diet-induced fatty liver in mice. Sci Rep 2015;5:10457. [PMID: 26179949 DOI: 10.1038/srep10457] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
449 Stepanova M, Younossi ZM. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol. 2012;10:646-650. [PMID: 22245962 DOI: 10.1016/j.cgh.2011.12.039] [Cited by in Crossref: 189] [Cited by in F6Publishing: 166] [Article Influence: 21.0] [Reference Citation Analysis]
450 Fruci B, Giuliano S, Mazza A, Malaguarnera R, Belfiore A. Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment. Int J Mol Sci. 2013;14:22933-22966. [PMID: 24264040 DOI: 10.3390/ijms141122933] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 7.8] [Reference Citation Analysis]
451 Pathil A, Liebisch G, Okun JG, Chamulitrat W, Schmitz G, Stremmel W. Ursodeoxycholyl Lysophosphatidylethanolamide modifies aberrant lipid profiles in NAFLD. Eur J Clin Invest 2015;45:925-31. [DOI: 10.1111/eci.12486] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
452 Golabi P, Bush H, Stepanova M, Locklear CT, Jacobson IM, Mishra A, Trimble G, Erario M, Venkatesan C, Younossi I, Goodman Z, Younossi ZM. Liver Transplantation (LT) for Cryptogenic Cirrhosis (CC) and Nonalcoholic Steatohepatitis (NASH) Cirrhosis: Data from the Scientific Registry of Transplant Recipients (SRTR): 1994 to 2016. Medicine (Baltimore). 2018;97:e11518. [PMID: 30075518 DOI: 10.1097/md.0000000000011518] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 8.3] [Reference Citation Analysis]
453 Oseini AM, Cole BK, Issa D, Feaver RE, Sanyal AJ. Translating scientific discovery: the need for preclinical models of nonalcoholic steatohepatitis. Hepatol Int 2018;12:6-16. [PMID: 29299759 DOI: 10.1007/s12072-017-9838-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
454 Ulmasov B, Noritake H, Carmichael P, Oshima K, Griggs DW, Neuschwander-Tetri BA. An Inhibitor of Arginine-Glycine-Aspartate-Binding Integrins Reverses Fibrosis in a Mouse Model of Nonalcoholic Steatohepatitis. Hepatol Commun 2019;3:246-61. [PMID: 30766962 DOI: 10.1002/hep4.1298] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
455 Kineman RD, Majumdar N, Subbaiah PV, Cordoba-Chacon J. Hepatic PPARγ Is Not Essential for the Rapid Development of Steatosis After Loss of Hepatic GH Signaling, in Adult Male Mice. Endocrinology 2016;157:1728-35. [PMID: 26950202 DOI: 10.1210/en.2015-2077] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
456 Hyötyläinen T, Orešič M. Systems biology strategies to study lipidomes in health and disease. Progress in Lipid Research 2014;55:43-60. [DOI: 10.1016/j.plipres.2014.06.001] [Cited by in Crossref: 54] [Cited by in F6Publishing: 35] [Article Influence: 7.7] [Reference Citation Analysis]
457 Gitto S, Vitale G, Villa E, Andreone P. Treatment of nonalcoholic steatohepatitis in adults: present and future. Gastroenterol Res Pract. 2015;2015:732870. [PMID: 25866507 DOI: 10.1155/2015/732870] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
458 Do A, Reau NS. Chronic Viral Hepatitis: Current Management and Future Directions. Hepatol Commun 2020;4:329-41. [PMID: 32140652 DOI: 10.1002/hep4.1480] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 13.0] [Reference Citation Analysis]
459 Hirode G, Saab S, Wong RJ. Trends in the Burden of Chronic Liver Disease Among Hospitalized US Adults. JAMA Netw Open 2020;3:e201997. [PMID: 32239220 DOI: 10.1001/jamanetworkopen.2020.1997] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 19.0] [Reference Citation Analysis]
460 Paik J, Golabi P, Younoszai Z, Mishra A, Trimble G, Younossi ZM, Negro F. Chronic kidney disease is independently associated with increased mortality in patients with nonalcoholic fatty liver disease. Liver Int 2019;39:342-52. [DOI: 10.1111/liv.13992] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
461 Chen LD, Zhang LJ, Lin XJ, Qi JC, Li H, Wu Z, Xu QZ, Huang YP, Lin L. Association between continuous positive airway pressure and serum aminotransferases in patients with obstructive sleep apnea. Eur Arch Otorhinolaryngol. 2018;275:587-594. [PMID: 29224042 DOI: 10.1007/s00405-017-4840-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
462 Satapathy SK, Kuwajima V, Nadelson J, Atiq O, Sanyal AJ. Drug-induced fatty liver disease: An overview of pathogenesis and management. Ann Hepatol 2015;14:789-806. [PMID: 26436351 DOI: 10.5604/16652681.1171749] [Cited by in Crossref: 35] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
463 Méndez-Sánchez N, Zamarripa-Dorsey F, Panduro A, Purón-González E, Coronado-Alejandro EU, Cortez-Hernández CA, Higuera de la Tijera F, Pérez-Hernández JL, Cerda-Reyes E, Rodríguez-Hernández H, Cruz-Ramón VC, Ramírez-Pérez OL, Aguilar-Olivos NE, Rodríguez-Martínez OF, Cabrera-Palma S, Cabrera-Álvarez G. Current trends of liver cirrhosis in Mexico: Similitudes and differences with other world regions. World J Clin Cases 2018;6:922-30. [PMID: 30568947 DOI: 10.12998/wjcc.v6.i15.922] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
464 Parker R, Kim SJ, Gao B. Alcohol, adipose tissue and liver disease: mechanistic links and clinical considerations. Nat Rev Gastroenterol Hepatol. 2018;15:50-59. [PMID: 28930290 DOI: 10.1038/nrgastro.2017.116] [Cited by in Crossref: 58] [Cited by in F6Publishing: 43] [Article Influence: 14.5] [Reference Citation Analysis]
465 Brauer DG, Nywening TM, Jaques DP, Doyle MB, Chapman WC, Fields RC, Hawkins WG. Operative Site Drainage after Hepatectomy: A Propensity Score Matched Analysis Using the American College of Surgeons NSQIP Targeted Hepatectomy Database. J Am Coll Surg 2016;223:774-783.e2. [PMID: 27793459 DOI: 10.1016/j.jamcollsurg.2016.09.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
466 Rustgi VK, Li Y, John T, Catalano C, Elsaid MI. Health Care Resource Use and Cost Burden of Chronic Kidney Disease in Patients With Chronic Liver Disease: A Real-World Claims Analysis. Hepatol Commun. 2020;4:1404-1418. [PMID: 33024912 DOI: 10.1002/hep4.1573] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
467 Stoopen-Rometti M, Encinas-Escobar ER, Ramirez-Carmona CR, Wolpert-Barraza E, Kimura-Hayama E, Sosa-Lozano LA, Favila R, Kimura-Fujikami Y, Saavedra-Abril JA, Loaeza-Del Castillo A. Diagnosis and quantification of fibrosis, steatosis, and hepatic siderosis through multiparametric magnetic resonance imaging. Rev Gastroenterol Mex 2017;82:32-45. [PMID: 28089429 DOI: 10.1016/j.rgmx.2016.06.001] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
468 Pimentel CF, Jiang ZG, Otsubo T, Feldbrügge L, Challies TL, Nasser I, Robson S, Afdhal N, Lai M. Poor Inter-test Reliability Between CK18 Kits as a Biomarker of NASH. Dig Dis Sci 2016;61:905-12. [PMID: 26462489 DOI: 10.1007/s10620-015-3916-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
469 Boursier J, Vergniol J, Guillet A, Hiriart J, Lannes A, Le Bail B, Michalak S, Chermak F, Bertrais S, Foucher J, Oberti F, Charbonnier M, Fouchard-hubert I, Rousselet M, Calès P, de Lédinghen V. Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease. Journal of Hepatology 2016;65:570-8. [DOI: 10.1016/j.jhep.2016.04.023] [Cited by in Crossref: 183] [Cited by in F6Publishing: 142] [Article Influence: 36.6] [Reference Citation Analysis]
470 Ofosu A, Ramai D, Reddy M. Non-alcoholic fatty liver disease: controlling an emerging epidemic, challenges, and future directions. Ann Gastroenterol. 2018;31:288-295. [PMID: 29720854 DOI: 10.20524/aog.2018.0240] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 4.7] [Reference Citation Analysis]
471 Eder SK, Feldman A, Strebinger G, Kemnitz J, Zandanell S, Niederseer D, Strasser M, Haufe H, Sotlar K, Stickel F, Paulweber B, Datz C, Aigner E. Mesenchymal iron deposition is associated with adverse long-term outcome in non-alcoholic fatty liver disease. Liver Int 2020;40:1872-82. [PMID: 32378295 DOI: 10.1111/liv.14503] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
472 Boursier J, Calès P. Controlled attenuation parameter (CAP): a new device for fast evaluation of liver fat? Liver Int. 2012;32:875-877. [PMID: 22672640 DOI: 10.1111/j.1478-3231.2012.02824.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
473 Robinson A, Ohri A, Liu B, Bhuket T, Wong RJ. One in five hepatocellular carcinoma patients in the United States are Hispanic while less than 40% were eligible for liver transplantation. World J Hepatol 2018;10:956-65. [PMID: 30631400 DOI: 10.4254/wjh.v10.i12.956] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
474 Bajantri B, Lvovsky D. A Case of Concomitant Obstructive Sleep Apnea and Non-Alcoholic Steatohepatitis Treated With CPAP Therapy. Gastroenterology Res. 2018;11:252-259. [PMID: 29915639 DOI: 10.14740/gr1033w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
475 Harrison MF. The Misunderstood Coagulopathy of Liver Disease: A Review for the Acute Setting. West J Emerg Med. 2018;19:863-871. [PMID: 30202500 DOI: 10.5811/westjem.2018.7.37893] [Cited by in Crossref: 30] [Cited by in F6Publishing: 14] [Article Influence: 10.0] [Reference Citation Analysis]
476 Tan HY, San-Marina S, Wang N, Hong M, Li S, Li L, Cheung F, Wen XY, Feng Y. Preclinical Models for Investigation of Herbal Medicines in Liver Diseases: Update and Perspective. Evid Based Complement Alternat Med. 2016;2016:1-26. [PMID: 26941826 DOI: 10.1155/2016/4750163] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
477 Xia MF, Ling Y, Bian H, Lin HD, Yan HM, Chang XX, Li XM, Ma H, Wang D, Zhang LS. I148M variant of PNPLA3 increases the susceptibility to non-alcoholic fatty liver disease caused by obesity and metabolic disorders. Aliment Pharmacol Ther. 2016;43:631-642. [PMID: 26765961 DOI: 10.1111/apt.13521] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
478 Reddy SK, Zhan M, Alexander HR, El-Kamary SS. Nonalcoholic fatty liver disease is associated with benign gastrointestinal disorders. World J Gastroenterol. 2013;19:8301-8311. [PMID: 24363521 DOI: 10.3748/wjg.v19.i45.8301] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 17] [Article Influence: 3.1] [Reference Citation Analysis]
479 Karsdal MA, Manon-Jensen T, Genovese F, Kristensen JH, Nielsen MJ, Sand JM, Hansen NU, Bay-Jensen AC, Bager CL, Krag A, Blanchard A, Krarup H, Leeming DJ, Schuppan D. Novel insights into the function and dynamics of extracellular matrix in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2015;308:G807-30. [PMID: 25767261 DOI: 10.1152/ajpgi.00447.2014] [Cited by in Crossref: 138] [Cited by in F6Publishing: 122] [Article Influence: 23.0] [Reference Citation Analysis]
480 Boursier J, Rousselet M, Aubé C, Calès P. Liver fibrosis in patients with non-alcoholic fatty liver disease: diagnostic options in clinical practice. Expert Opinion on Medical Diagnostics 2012;6:381-94. [DOI: 10.1517/17530059.2012.691878] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
481 Ismaiel A, Dumitraşcu DL. Cardiovascular Risk in Fatty Liver Disease: The Liver-Heart Axis-Literature Review. Front Med (Lausanne) 2019;6:202. [PMID: 31616668 DOI: 10.3389/fmed.2019.00202] [Cited by in Crossref: 37] [Cited by in F6Publishing: 26] [Article Influence: 18.5] [Reference Citation Analysis]
482 Khoudari G, Singh A, Noureddin M, Fritze D, Lopez R, Asaad I, Lawitz E, Poordad F, Kowdley KV, Alkhouri N. Characterization of patients with both alcoholic and nonalcoholic fatty liver disease in a large United States cohort. World J Hepatol 2019;11:710-8. [PMID: 31749901 DOI: 10.4254/wjh.v11.i10.710] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
483 Patel YA, Gifford EJ, Glass LM, McNeil R, Turner MJ, Han B, Provenzale D, Choi SS, Moylan CA, Hunt CM. Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration. Aliment Pharmacol Ther 2018;47:268-78. [PMID: 29115682 DOI: 10.1111/apt.14411] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
484 Duncan M, Zong W, Biank VF, Hageman JR. Nonalcoholic Fatty Liver Disease in Pediatrics. Pediatr Ann 2016;45:e54-8. [PMID: 26878184 DOI: 10.3928/00904481-20160113-01] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
485 Fazeli Dehkordy S, Fowler KJ, Mamidipalli A, Wolfson T, Hong CW, Covarrubias Y, Hooker JC, Sy EZ, Schlein AN, Cui JY, Gamst AC, Hamilton G, Reeder SB, Sirlin CB. Hepatic steatosis and reduction in steatosis following bariatric weight loss surgery differs between segments and lobes. Eur Radiol 2019;29:2474-80. [PMID: 30547206 DOI: 10.1007/s00330-018-5894-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
486 Hajifathalian K, Torabi Sagvand B, McCullough AJ. Effect of Alcohol Consumption on Survival in Nonalcoholic Fatty Liver Disease: A National Prospective Cohort Study. Hepatology 2019;70:511-21. [PMID: 30125379 DOI: 10.1002/hep.30226] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 13.3] [Reference Citation Analysis]
487 Olveira A, Domínguez L, Troya J, Arias A, Pulido F, Ryan P, Benítez LM, González-García J, Montes ML; PALT-M-Study Group Investigators. Persistently altered liver test results in hepatitis C patients after sustained virological response with direct-acting antivirals. J Viral Hepat 2018;25:818-24. [PMID: 29476581 DOI: 10.1111/jvh.12883] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
488 Chung M, Ma J, Patel K, Berger S, Lau J, Lichtenstein AH. Fructose, high-fructose corn syrup, sucrose, and nonalcoholic fatty liver disease or indexes of liver health: a systematic review and meta-analysis. Am J Clin Nutr 2014;100:833-49. [PMID: 25099546 DOI: 10.3945/ajcn.114.086314] [Cited by in Crossref: 126] [Cited by in F6Publishing: 114] [Article Influence: 18.0] [Reference Citation Analysis]
489 Tziomalos K, Athyros VG, Paschos P, Karagiannis A. Nonalcoholic fatty liver disease and statins. Metabolism. 2015;64:1215-1223. [PMID: 26234727 DOI: 10.1016/j.metabol.2015.07.003] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 7.8] [Reference Citation Analysis]
490 Mellor TE, Torres DM. Editorial: lean and obese NAFLD-similar siblings. Aliment Pharmacol Ther 2017;46:549-50. [DOI: 10.1111/apt.14196] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
491 Li Y, Liu L, Wang B, Xiong J, Li Q, Wang J, Chen D. Impairment of reproductive function in a male rat model of non-alcoholic fatty liver disease and beneficial effect of N-3 fatty acid supplementation. Toxicology Letters 2013;222:224-32. [DOI: 10.1016/j.toxlet.2013.05.644] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 4.4] [Reference Citation Analysis]
492 Burhans MS, Balu N, Schmidt KA, Cromer G, Utzschneider KM, Schur EA, Holte SE, Randolph TW, Kratz M. Impact of the Analytical Approach on the Reliability of MRI-Based Assessment of Hepatic Fat Content. Curr Dev Nutr 2020;4:nzaa171. [PMID: 33381677 DOI: 10.1093/cdn/nzaa171] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
493 Yasutake K, Kohjima M, Kotoh K, Nakashima M, Nakamuta M, Enjoji M. Dietary habits and behaviors associated with nonalcoholic fatty liver disease. World J Gastroenterol 2014;20:1756-67. [PMID: 24587653 DOI: 10.3748/wjg.v20.i7.1756] [Cited by in CrossRef: 59] [Cited by in F6Publishing: 50] [Article Influence: 9.8] [Reference Citation Analysis]
494 Makri E, Goulas A, Polyzos SA. Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease.Arch Med Res. 2021;52:25-37. [PMID: 33334622 DOI: 10.1016/j.arcmed.2020.11.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
495 Koch M, Nöthlings U, Lieb W. Dietary patterns and fatty liver disease. Curr Opin Lipidol 2015;26:35-41. [PMID: 25501880 DOI: 10.1097/MOL.0000000000000141] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
496 Sharifnia T, Antoun J, Verriere TG, Suarez G, Wattacheril J, Wilson KT, Peek RM, Abumrad NN, Flynn CR. Hepatic TLR4 signaling in obese NAFLD. Am J Physiol Gastrointest Liver Physiol. 2015;309:G270-G278. [PMID: 26113297 DOI: 10.1152/ajpgi.00304.2014.Epub] [Reference Citation Analysis]
497 Solfrizzi V, Scafato E, Custodero C, Loparco F, Ciavarella A, Panza F, Seripa D, Imbimbo BP, Lozupone M, Napoli N, Piazzolla G, Galluzzo L, Gandin C, Baldereschi M, Di Carlo A, Inzitari D, Pilotto A, Sabbà C; Italian Longitudinal Study on Aging Working Group. Liver fibrosis score, physical frailty, and the risk of dementia in older adults: The Italian Longitudinal Study on Aging. Alzheimers Dement (N Y) 2020;6:e12065. [PMID: 32864415 DOI: 10.1002/trc2.12065] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
498 Younossi ZM, Otgonsuren M, Venkatesan C, Mishra A. In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not. Metabolism 2013;62:352-60. [DOI: 10.1016/j.metabol.2012.08.005] [Cited by in Crossref: 90] [Cited by in F6Publishing: 90] [Article Influence: 11.3] [Reference Citation Analysis]
499 Bray GA, Heisel WE, Afshin A, Jensen MD, Dietz WH, Long M, Kushner RF, Daniels SR, Wadden TA, Tsai AG, Hu FB, Jakicic JM, Ryan DH, Wolfe BM, Inge TH. The Science of Obesity Management: An Endocrine Society Scientific Statement. Endocr Rev. 2018;39:79-132. [PMID: 29518206 DOI: 10.1210/er.2017-00253] [Cited by in Crossref: 229] [Cited by in F6Publishing: 160] [Article Influence: 114.5] [Reference Citation Analysis]
500 Patel SS, Nabi E, Guzman L, Abbate A, Bhati C, Stravitz RT, Reichman T, Matherly SC, Driscoll C, Lee H, Luketic VA, Sterling RK, Sanyal AJ, Patel V, Levy M, Siddiqui MS. Coronary artery disease in decompensated patients undergoing liver transplantation evaluation. Liver Transpl. 2018;24:333-342. [PMID: 29328556 DOI: 10.1002/lt.25012] [Cited by in Crossref: 40] [Cited by in F6Publishing: 28] [Article Influence: 13.3] [Reference Citation Analysis]
501 Luo J, Wu X, Zhang Y, Huang W, Jia B. Role of ascitic prostaglandin E2 in diagnosis of spontaneous bacterial peritonitis and prediction of in-hospital mortality in patients with decompensated cirrhosis. Medicine (Baltimore) 2019;98:e16016. [PMID: 31261505 DOI: 10.1097/MD.0000000000016016] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
502 Tu LN, Showalter MR, Cajka T, Fan S, Pillai VV, Fiehn O, Selvaraj V. Metabolomic characteristics of cholesterol-induced non-obese nonalcoholic fatty liver disease in mice. Sci Rep 2017;7:6120. [PMID: 28733574 DOI: 10.1038/s41598-017-05040-6] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 9.3] [Reference Citation Analysis]
503 Lim HW, Bernstein DE. Risk Factors for the Development of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Genetics. Clin Liver Dis 2018;22:39-57. [PMID: 29128060 DOI: 10.1016/j.cld.2017.08.008] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
504 Noureddin M, Anstee QM, Loomba R. Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2016;43:1109-23. [PMID: 27061197 DOI: 10.1111/apt.13620] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
505 Freitas RB, Novaes RD, Gonçalves RV, Mendonça BG, Santos EC, Ribeiro AQ, Lima LM, Fietto LG, Peluzio Mdo C, Leite JP. Euterpe edulis Extract but Not Oil Enhances Antioxidant Defenses and Protects against Nonalcoholic Fatty Liver Disease Induced by a High-Fat Diet in Rats. Oxid Med Cell Longev 2016;2016:8173876. [PMID: 27418954 DOI: 10.1155/2016/8173876] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
506 Kolachala VL, Palle S, Shen M, Feng A, Shayakhmetov D, Gupta NA. Loss of L-selectin-guided CD8+ , but not CD4+ , cells protects against ischemia reperfusion injury in a steatotic liver. Hepatology 2017;66:1258-74. [PMID: 28543181 DOI: 10.1002/hep.29276] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
507 Tuyama AC, Chang CY. Non-alcoholic fatty liver disease: Non-alcoholic fatty liver disease. Journal of Diabetes 2012;4:266-80. [DOI: 10.1111/j.1753-0407.2012.00204.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
508 Clements O, Eliahoo J, Kim JU, Taylor-Robinson SD, Khan SA. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis. J Hepatol. 2020;72:95-103. [PMID: 31536748 DOI: 10.1016/j.jhep.2019.09.007] [Cited by in Crossref: 63] [Cited by in F6Publishing: 54] [Article Influence: 31.5] [Reference Citation Analysis]
509 Cui Y, Chang R, Zhang T, Zhou X, Wang Q, Gao H, Hou L, Loor JJ, Xu C. Chinese Herbal Formula (CHF03) Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) Through Inhibiting Lipogenesis and Anti-Oxidation Mechanisms. Front Pharmacol 2019;10:1190. [PMID: 31680967 DOI: 10.3389/fphar.2019.01190] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
510 Kondo T, Maruyama H, Sekimoto T, Shimada T, Takahashi M, Yokosuka O. Reversed portal flow: Clinical influence on the long-term outcomes in cirrhosis. World J Gastroenterol 2015;21:8894-902. [PMID: 26269679 DOI: 10.3748/wjg.v21.i29.8894] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.4] [Reference Citation Analysis]
511 Zelber-Sagi S, Godos J, Salomone F. Lifestyle changes for the treatment of nonalcoholic fatty liver disease: a review of observational studies and intervention trials. Therap Adv Gastroenterol. 2016;9:392-407. [PMID: 27134667 DOI: 10.1177/1756283x16638830] [Cited by in Crossref: 63] [Cited by in F6Publishing: 30] [Article Influence: 12.6] [Reference Citation Analysis]
512 Habig G, Smaltz C, Halegoua-DeMarzio D. Presence and Implications of Sarcopenia in Non-alcoholic Steatohepatitis. Metabolites 2021;11:242. [PMID: 33920751 DOI: 10.3390/metabo11040242] [Reference Citation Analysis]
513 Jung C, Lee B, Choi D, Jung S, Kim B, Kim C, Kang S, Mok J. Association of grade of non-alcoholic fatty liver disease and glycated albumin to glycated hemoglobin ratio in patients with type 2 diabetes mellitus. Diabetes Research and Clinical Practice 2017;125:53-61. [DOI: 10.1016/j.diabres.2016.12.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
514 Zhu C, Kim K, Wang X, Bartolome A, Salomao M, Dongiovanni P, Meroni M, Graham MJ, Yates KP, Diehl AM, Schwabe RF, Tabas I, Valenti L, Lavine JE, Pajvani UB. Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis. Sci Transl Med 2018;10:eaat0344. [PMID: 30463916 DOI: 10.1126/scitranslmed.aat0344] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 27.0] [Reference Citation Analysis]
515 Chen Y, Liu P, Liu R, Hu S, He Z, Dong G, Feng C, An S, Ying X. Comprehensive Strain-Level Analysis of the Gut Microbe Faecalibacterium prausnitzii in Patients with Liver Cirrhosis. mSystems 2021;6:e0077521. [PMID: 34342541 DOI: 10.1128/mSystems.00775-21] [Reference Citation Analysis]
516 Forsgren MF, Nasr P, Karlsson M, Dahlström N, Norén B, Ignatova S, Sinkus R, Cedersund G, Leinhard OD, Ekstedt M, Kechagias S, Lundberg P. Biomarkers of liver fibrosis: prospective comparison of multimodal magnetic resonance, serum algorithms and transient elastography. Scand J Gastroenterol 2020;55:848-59. [PMID: 32684060 DOI: 10.1080/00365521.2020.1786599] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
517 Mohammed H, Varoni EM, Cochis A, Cordaro M, Gallenzi P, Patini R, Staderini E, Lajolo C, Rimondini L, Rocchetti V. Oral Dysbiosis in Pancreatic Cancer and Liver Cirrhosis: A Review of the Literature. Biomedicines 2018;6:E115. [PMID: 30544974 DOI: 10.3390/biomedicines6040115] [Cited by in Crossref: 31] [Cited by in F6Publishing: 19] [Article Influence: 10.3] [Reference Citation Analysis]
518 Yang M, Wu E, Rao H, Du FH, Xie A, Cheng S, Rodd C, Lin A, Wei L, Lok AS. A Comparative Study of Liver Disease Care in the USA and Urban and Rural China. Dig Dis Sci 2016;61:2847-56. [PMID: 27256156 DOI: 10.1007/s10620-016-4206-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
519 Mir HM, Stepanova M, Afendy M, Kugelmas M, Younossi ZM. African americans are less likely to have clearance of hepatitis C virus infection: the findings from recent U.S. population data. J Clin Gastroenterol 2012;46:e62-5. [PMID: 22178959 DOI: 10.1097/MCG.0b013e318238352b] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
520 Weiss J, Rau M, Meertens J, Hering I, Reichert L, Kudlich T, Koschker A, Jurowich C, Geier A. Feasibility of liver stiffness measurement in morbidly obese patients undergoing bariatric surgery using XL probe. Scandinavian Journal of Gastroenterology 2016;51:1263-8. [DOI: 10.1080/00365521.2016.1191084] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
521 Stepanova M, Rafiq N, Makhlouf H, Agrawal R, Kaur I, Younoszai Z, McCullough A, Goodman Z, Younossi ZM. Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci. 2013;58:3017-3023. [PMID: 23775317 DOI: 10.1007/s10620-013-2743-5] [Cited by in Crossref: 152] [Cited by in F6Publishing: 139] [Article Influence: 19.0] [Reference Citation Analysis]
522 Asrih M, Jornayvaz FR. Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistance. Journal of Endocrinology 2013;218:R25-36. [DOI: 10.1530/joe-13-0201] [Cited by in Crossref: 155] [Cited by in F6Publishing: 72] [Article Influence: 19.4] [Reference Citation Analysis]
523 Soeda J, Cordero P, Li J, Mouralidarane A, Asilmaz E, Ray S, Nguyen V, Carter R, Novelli M, Vinciguerra M, Poston L, Taylor PD, Oben JA. Hepatic rhythmicity of endoplasmic reticulum stress is disrupted in perinatal and adult mice models of high-fat diet-induced obesity. Int J Food Sci Nutr 2017;68:455-66. [PMID: 27899042 DOI: 10.1080/09637486.2016.1261086] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
524 Jiang ZG, Mukamal K, Tapper E, Robson SC, Tsugawa Y. Low LDL-C and high HDL-C levels are associated with elevated serum transaminases amongst adults in the United States: a cross-sectional study. PLoS One 2014;9:e85366. [PMID: 24454851 DOI: 10.1371/journal.pone.0085366] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
525 Zhang J, Zhang B, Cheng Y, Xu J. Low serum CTRP3 levels are associated with nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. Cytokine 2018;106:131-5. [DOI: 10.1016/j.cyto.2017.10.023] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
526 Verderese JP, Younossi Z. Interaction of type 2 diabetes and nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol 2013;7:405-7. [PMID: 23899279 DOI: 10.1586/17474124.2013.811047] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
527 Bian H, Hakkarainen A, Zhou Y, Lundbom N, Olkkonen VM, Yki-Järvinen H. Impact of non-alcoholic fatty liver disease on liver volume in humans.Hepatol Res. 2015;45:210-219. [PMID: 24698021 DOI: 10.1111/hepr.12338] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
528 Marcher AB, Bendixen SM, Terkelsen MK, Hohmann SS, Hansen MH, Larsen BD, Mandrup S, Dimke H, Detlefsen S, Ravnskjaer K. Transcriptional regulation of Hepatic Stellate Cell activation in NASH. Sci Rep 2019;9:2324. [PMID: 30787418 DOI: 10.1038/s41598-019-39112-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 13.5] [Reference Citation Analysis]
529 Goh GB, Chow WC, Wang R, Yuan JM, Koh WP. Coffee, alcohol and other beverages in relation to cirrhosis mortality: the Singapore Chinese Health Study. Hepatology. 2014;60:661-669. [PMID: 24753005 DOI: 10.1002/hep.27054] [Cited by in Crossref: 38] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
530 Hirode G, Vittinghoff E, Wong RJ. Increasing Clinical and Economic Burden of Nonalcoholic Fatty Liver Disease Among Hospitalized Adults in the United States. J Clin Gastroenterol. 2019;53:765-771. [PMID: 31135632 DOI: 10.1097/mcg.0000000000001229] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
531 Rippe JM, Sievenpiper JL, Lê KA, White JS, Clemens R, Angelopoulos TJ. What is the appropriate upper limit for added sugars consumption? Nutr Rev 2017;75:18-36. [PMID: 27974597 DOI: 10.1093/nutrit/nuw046] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 4.8] [Reference Citation Analysis]
532 Jiang ZG, Tapper EB, Connelly MA, Pimentel CF, Feldbrügge L, Kim M, Krawczyk S, Afdhal N, Robson SC, Herman MA, Otvos JD, Mukamal KJ, Lai M. Steatohepatitis and liver fibrosis are predicted by the characteristics of very low density lipoprotein in nonalcoholic fatty liver disease. Liver Int 2016;36:1213-20. [PMID: 26815314 DOI: 10.1111/liv.13076] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
533 Hejlova I, Honsova E, Sticova E, Lanska V, Hucl T, Spicak J, Jirsa M, Trunecka P. Prevalence and risk factors of steatosis after liver transplantation and patient outcomes. Liver Transpl. 2016;22:644-655. [PMID: 26707008 DOI: 10.1002/lt.24393] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
534 Shaker M, Tabbaa A, Albeldawi M, Alkhouri N. Liver transplantation for nonalcoholic fatty liver disease: new challenges and new opportunities. World J Gastroenterol. 2014;20:5320-5330. [PMID: 24833862 DOI: 10.3748/wjg.v20.i18.5320] [Cited by in CrossRef: 60] [Cited by in F6Publishing: 53] [Article Influence: 10.0] [Reference Citation Analysis]
535 Willemin G, Roger C, Bauduret A, Minehira K. Major Histocompatibility Class II Pathway Is Not Required for the Development of Nonalcoholic Fatty Liver Disease in Mice. Int J Endocrinol 2013;2013:972962. [PMID: 23710178 DOI: 10.1155/2013/972962] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
536 Bouret S, Levin BE, Ozanne SE. Gene-environment interactions controlling energy and glucose homeostasis and the developmental origins of obesity. Physiol Rev 2015;95:47-82. [PMID: 25540138 DOI: 10.1152/physrev.00007.2014] [Cited by in Crossref: 85] [Cited by in F6Publishing: 65] [Article Influence: 14.2] [Reference Citation Analysis]
537 Dallak M. Crataegus aronia enhances sperm parameters and preserves testicular architecture in both control and non-alcoholic fatty liver disease-induced rats. Pharm Biol 2018;56:535-47. [PMID: 30375253 DOI: 10.1080/13880209.2018.1523934] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
538 Kishida Y, Okubo H, Ohno H, Oki K, Yoneda M. Effect of miglitol on the suppression of nonalcoholic steatohepatitis development and improvement of the gut environment in a rodent model. J Gastroenterol. 2017;52:1180-1191. [PMID: 28349245 DOI: 10.1007/s00535-017-1331-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
539 Kim D, Li AA, Gadiparthi C, Khan MA, Cholankeril G, Glenn JS, Ahmed A. Changing Trends in Etiology-Based Annual Mortality From Chronic Liver Disease, From 2007 Through 2016. Gastroenterology. 2018;155:1154-1163.e3. [PMID: 30009816 DOI: 10.1053/j.gastro.2018.07.008] [Cited by in Crossref: 90] [Cited by in F6Publishing: 76] [Article Influence: 30.0] [Reference Citation Analysis]
540 Hu W, Yang H, Xu H, Mao Y. Radiomics based on artificial intelligence in liver diseases: where we are? Gastroenterol Rep (Oxf) 2020;8:90-7. [PMID: 32280468 DOI: 10.1093/gastro/goaa011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
541 Alkhouri N, Singh T, Alsabbagh E, Guirguis J, Chami T, Hanouneh I, Grove D, Lopez R, Dweik R. Isoprene in the Exhaled Breath is a Novel Biomarker for Advanced Fibrosis in Patients with Chronic Liver Disease: A Pilot Study. Clin Transl Gastroenterol 2015;6:e112. [PMID: 26378385 DOI: 10.1038/ctg.2015.40] [Cited by in Crossref: 38] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
542 Bazick J, Donithan M, Neuschwander-Tetri BA, Kleiner D, Brunt EM, Wilson L, Doo E, Lavine J, Tonascia J, Loomba R. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD. Diabetes Care. 2015;38:1347-1355. [PMID: 25887357 DOI: 10.2337/dc14-1239] [Cited by in Crossref: 101] [Cited by in F6Publishing: 77] [Article Influence: 16.8] [Reference Citation Analysis]
543 Heathcote EJ. Clinical trials and their translation in hepatology: Past, present, and future. Hepatology 2012;56:399-410. [DOI: 10.1002/hep.25557] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
544 Kabbany MN, Conjeevaram Selvakumar PK, Watt K, Lopez R, Akras Z, Zein N, Carey W, Alkhouri N. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data. Am J Gastroenterol. 2017;112:581-587. [PMID: 28195177 DOI: 10.1038/ajg.2017.5] [Cited by in Crossref: 102] [Cited by in F6Publishing: 80] [Article Influence: 25.5] [Reference Citation Analysis]
545 Okubo H, Kushiyama A, Nakatsu Y, Yamamotoya T, Matsunaga Y, Fujishiro M, Sakoda H, Ohno H, Yoneda M, Asano T. Roles of Gut-Derived Secretory Factors in the Pathogenesis of Non-Alcoholic Fatty Liver Disease and Their Possible Clinical Applications. Int J Mol Sci 2018;19:E3064. [PMID: 30297626 DOI: 10.3390/ijms19103064] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
546 Drolz A, Wolter S, Wehmeyer MH, Piecha F, Horvatits T, Schulze Zur Wiesch J, Lohse AW, Mann O, Kluwe J. Performance of non-invasive fibrosis scores in non-alcoholic fatty liver disease with and without morbid obesity. Int J Obes (Lond) 2021. [PMID: 34168277 DOI: 10.1038/s41366-021-00881-8] [Reference Citation Analysis]
547 Reynés B, García-ruiz E, Díaz-rúa R, Palou A, Oliver P. Reversion to a control balanced diet is able to restore body weight and to recover altered metabolic parameters in adult rats long-term fed on a cafeteria diet. Food Research International 2014;64:839-48. [DOI: 10.1016/j.foodres.2014.08.012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
548 Long MT, Yin X, Larson MG, Ellinor PT, Lubitz SA, McManus DD, Magnani JW, Staerk L, Ko D, Helm RH, Hoffmann U, Chung RT, Benjamin EJ. Relations of Liver Fat With Prevalent and Incident Atrial Fibrillation in the Framingham Heart Study. J Am Heart Assoc 2017;6:e005227. [PMID: 28465298 DOI: 10.1161/JAHA.116.005227] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 3.8] [Reference Citation Analysis]
549 Ladhani S, Ohri A, Wong RJ. Disparities in Hepatocellular Carcinoma Surveillance: Dissecting the Roles of Patient, Provider, and Health System Factors. Journal of Clinical Gastroenterology 2020;54:218-26. [DOI: 10.1097/mcg.0000000000001313] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
550 Iqbal U, Perumpail BJ, Akhtar D, Kim D, Ahmed A. The Epidemiology, Risk Profiling and Diagnostic Challenges of Nonalcoholic Fatty Liver Disease. Medicines (Basel). 2019;6. [PMID: 30889791 DOI: 10.3390/medicines6010041] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 18.0] [Reference Citation Analysis]
551 Long MT, Pedley A, Massaro JM, Hoffmann U, Esliger DW, Vasan RS, Fox CS, Murabito JM. Hepatic steatosis is associated with lower levels of physical activity measured via accelerometry. Obesity (Silver Spring) 2015;23:1259-66. [PMID: 25959049 DOI: 10.1002/oby.21058] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
552 Kim D, Ahmed A, Kushida C. Continuous positive airway pressure therapy on nonalcoholic fatty liver disease in patients with obstructive sleep apnea. J Clin Sleep Med. 2018;14:1315-1322. [PMID: 30092894 DOI: 10.5664/jcsm.7262] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
553 Mellinger JL, Shedden K, Winder GS, Tapper E, Adams M, Fontana RJ, Volk ML, Blow FC, Lok ASF. The high burden of alcoholic cirrhosis in privately insured persons in the United States. Hepatology. 2018;68:872-882. [PMID: 29579356 DOI: 10.1002/hep.29887] [Cited by in Crossref: 83] [Cited by in F6Publishing: 67] [Article Influence: 27.7] [Reference Citation Analysis]
554 Ward LD, Tu HC, Quenneville CB, Tsour S, Flynn-Carroll AO, Parker MM, Deaton AM, Haslett PAJ, Lotta LA, Verweij N, Ferreira MAR, Baras A, Hinkle G, Nioi P; Regeneron Genetics Center., Geisinger-Regeneron DiscovEHR Collaboration. GWAS of serum ALT and AST reveals an association of SLC30A10 Thr95Ile with hypermanganesemia symptoms. Nat Commun 2021;12:4571. [PMID: 34315874 DOI: 10.1038/s41467-021-24563-1] [Reference Citation Analysis]
555 Oloruntoba OO, Moylan CA. Gender-based disparities in access to and outcomes of liver transplantation. World J Hepatol 2015;7:460-7. [PMID: 25848470 DOI: 10.4254/wjh.v7.i3.460] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
556 Stepanova M, De Avila L, Afendy M, Younossi I, Pham H, Cable R, Younossi ZM. Direct and Indirect Economic Burden of Chronic Liver Disease in the United States. Clinical Gastroenterology and Hepatology 2017;15:759-766.e5. [DOI: 10.1016/j.cgh.2016.07.020] [Cited by in Crossref: 62] [Cited by in F6Publishing: 50] [Article Influence: 15.5] [Reference Citation Analysis]
557 Schulte L, Scheiner B, Voigtländer T, Koch S, Schweitzer N, Marhenke S, Ivanyi P, Manns MP, Rodt T, Hinrichs JB, Weinmann A, Pinter M, Vogel A, Kirstein MM. Treatment with metformin is associated with a prolonged survival in patients with hepatocellular carcinoma. Liver Int 2019;39:714-26. [PMID: 30663219 DOI: 10.1111/liv.14048] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 11.5] [Reference Citation Analysis]